1
|
Köse Ş, Yılmaz C, Kıratlı K, Çelebi Ç, Akan P, Kumas Kulualp M, Duman S, Yılmaz O. Effects of Repeated Doses of the Vero Cell Vaccine (SARS-Cov-2 Inactivated Vaccine) on Renal Functions in Balb/C Albino Mice. J Inflamm Res 2024; 17:2851-2860. [PMID: 38737106 PMCID: PMC11088834 DOI: 10.2147/jir.s455682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 04/20/2024] [Indexed: 05/14/2024] Open
Abstract
Objective Many of the vaccines developed for COVID-19 have been approved for clinical emergency use before their safety and preclinical studies have been completed. The main aim of this study was to investigate the effects of an inactivated SARS-CoV-2 virus vaccine (Vero cells) on renal function in Balb/C Albino mice. Methods 21 healthy, 6-8 week old BALB/c male mice were divided into three equal groups, and 0.10 mL of intramuscular saline equal to the vaccine dose volume was administered to the first group. To the second group, a single dose of 0.10 mL 120 U of Vero cell inactive SARS COV-2 vaccine was administered intramuscularly. Group 3 received two consecutive doses of 0.10 mL 120 U intramuscular Vero cell inactive SARS COV-2 vaccine, 14 days apart. After administration, the clinical status, fecal and urine status, nutritional status and kidney histopathology of the mice were evaluated. Results It was determined that no acute toxic symptoms were observed in the mice administered the vaccine, they were in good condition, and there was no significant stimulatory reaction related to the vaccine in the tissues of the injected local area. There was no difference in feed consumption, water consumption, and body weight gains between the control group, the groups that received a single dose of vaccine, and the groups that received two doses of vaccine (p>0.05). No difference was found between the groups when urine and feces amounts were compared (p>0.05). No difference was found between the groups when urinary urea, creatinine, and serum BUN, creatinine levels were compared (p>0.05). No difference was found in the histopathological evaluation of the kidneys between the groups (p>0.05). Conclusion In conclusion, single or repeated injections of the SARS-CoV-2 vaccine (Vero cells) into mice were found to have no adverse effects on the animals' overall clinical health, performance abilities and kidneys.
Collapse
Affiliation(s)
- Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
| | - Canberk Yılmaz
- Department of Pediatrics, Faculty of Medicine, Health Sciences University, Izmir, Turkey
| | - Kazım Kıratlı
- Department of Infectious Diseases and Clinical Microbiology, Mogadishu Somalia Turkey Recep Tayyip Erdoğan Training and Research Hospital, Mogadishu, Somalia
| | - Çağlar Çelebi
- Department of Medical Biology, Institute of Health Sciences, Ege University, Izmir, Turkey
| | - Pınar Akan
- Department of Medical Biochemistry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
| | - Meltem Kumas Kulualp
- Department of Histology and Embryology, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey
| | - Soner Duman
- Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Osman Yılmaz
- Department of Laboratory Animal Science, Institute of Health Sciences, Dokuz Eylul University, Izmir, Turkey
| |
Collapse
|
2
|
Yıldırım S, Kirakli C, Özdemir Y, Tosun S, Ermin S, Polat G, Yılmaz C, Bilaçeroğlu S, Salık B, Kömürcüoğlu B, Ödemiş İ, Köse Ş, Uzun U, Aydın G, İlhan E. Impact of vaccination on ICU admissions of hospitalized COVID-19 patients in a country with a heterologous vaccine policy. J Infect Dev Ctries 2024; 18:513-519. [PMID: 38728641 DOI: 10.3855/jidc.18342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Accepted: 10/14/2023] [Indexed: 05/12/2024] Open
Abstract
INTRODUCTION Vaccination against coronavirus disease-19 (COVID-19) is highly effective in preventing severe disease and mortality. Adenoviral vector and mRNA vaccines were effective against intensive care unit (ICU) admission, but the effectiveness of inactivated vaccine on ICU admission was unclear. We aimed to evaluate the effect of vaccination status on ICU admission in hospitalized COVID-19 patients in a country with heterologous vaccination policy. METHODOLOGY This is a retrospective multicenter study conducted in three hospitals in Izmir, Turkey between 1 January 2021 and 31 March 2022. Patients aged ≥ 18 years and hospitalized due to COVID-19 were included in the study. Patients who had never been vaccinated and patients who had been vaccinated with a single dose were considered unvaccinated. A logistic regression analysis was performed for evaluating risk factors for ICU admission. RESULTS A total of 2,110 patients were included in the final analysis. The median age was 66 years (IQR, 53-76 years) and 54% of the patients were vaccinated. During the study period, 407 patients (19.3%) were transferred to the ICU due to disease severity. Patients who were admitted to the ICU were older (median age 68 vs. 65 years, p < 0.001); and the number of unvaccinated individuals was higher among ICU patients (57% vs. 45%, p < 0.001). In multivariate regression analysis, being unvaccinated was found to be the most important independent risk factor for ICU admission with an OR of 2.06 (95% CI, 1.64-2.59). CONCLUSIONS Vaccination against COVID-19 is effective against ICU admission and hospital mortality.
Collapse
Affiliation(s)
- Süleyman Yıldırım
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Intensive Care Unit, Izmir, Turkey
| | - Cenk Kirakli
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Intensive Care Unit, Izmir, Turkey
| | - Yeliz Özdemir
- University of Health Sciences Turkey, Izmir School of Medicine, Bozyaka Training and Research Hospital, Department of Infectious Disease and Clinical Microbiology, Izmir, Turkey
| | - Selma Tosun
- University of Health Sciences Turkey, Izmir School of Medicine, Bozyaka Training and Research Hospital, Department of Infectious Disease and Clinical Microbiology, Izmir, Turkey
| | - Sinem Ermin
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - Gülru Polat
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - Celalettin Yılmaz
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - Semra Bilaçeroğlu
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - Bilge Salık
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - Berna Kömürcüoğlu
- University of Health Sciences Turkey, Izmir School of Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Department of Pulmonology, Izmir, Turkey
| | - İlker Ödemiş
- University of Health Sciences Turkey, Izmir Faculty of Medicine, Izmir Tepecik Training and Research Hospital, Department of Infectious Disease and Clinical Microbiology, Izmir, Turkey
| | - Şükran Köse
- University of Health Sciences Turkey, Izmir Faculty of Medicine, Izmir Tepecik Training and Research Hospital, Department of Infectious Disease and Clinical Microbiology, Izmir, Turkey
| | - Uğur Uzun
- University of Health Sciences Turkey, Izmir Faculty of Medicine, Izmir Tepecik Training and Research Hospital, Department of Anesthesiology and Reanimation, Izmir, Turkey
| | - Gaye Aydın
- University of Health Sciences Turkey, Izmir Faculty of Medicine, Izmir Tepecik Training and Research Hospital, Department of Anesthesiology and Reanimation, Izmir, Turkey
| | - Enver İlhan
- University of Health Sciences Turkey, Izmir Faculty of Medicine, Bozyaka Research and Training Hospital, Izmir, Turkey
| |
Collapse
|
3
|
Çelik Ekinci S, Yenilmez E, Akengin Öcal G, Sönmezer MÇ, Tarakçı A, Aygün C, Akdağ D, Seyman D, Aşık C, Zerdali E, Yılmaz Karadağ F, Kaya Ş, Çelik M, Çifci Ş, Yıldız İE, Çölkesen F, Akgül F, Aldemir Ö, Bozdağ M, Özer D, Hızmalı L, Canbolat Ünlü E, Gür Altunay D, Şahin A, Ünlü G, Gençalioğlu AE, Tekin Şahin S, Özdemir Y, Ünlü S, Singil S, Altıntaş J, Akkaya Işık S, Gül Ö, Tuna N, Şimşek S, Özgüler M, Elbir Kılıç P, Işık ME, Karakuş A, Kıratlı K, Yardımcı AC, Volkan S, Olçar Y, Çakır Y, Özer Yılmaz N, Karaayvaz S, Batırel A, Duran ZC, Raşa HK, Köse Ş. Surgical Antimicrobial Prophylaxis Compliance in Turkey: Data from the Prospective, Observational, Multicenter Survey Including 7,978 Surgical Patients. Surg Infect (Larchmt) 2024; 25:231-239. [PMID: 38588521 DOI: 10.1089/sur.2023.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2024] Open
Abstract
Background: Surgical antimicrobial prophylaxis (SAP) is the peri-operative administration of antimicrobial agents. Compliance rates vary worldwide from 15% to 84.3%, with studies in Turkey not exceeding 35%. The aim of this multicenter study was to determine the rate of appropriate antibiotic class, timing, and duration as well as discharge prescriptions in Turkey. Thus, we aimed to determine the rate of full compliance with SAP procedures in our country Patients and Methods: This multicenter, prospective, observational, descriptive study was conducted in 47 hospitals from 28 provinces in seven different regions of Turkey. Patients over 18 years of age in all surgical units between June 6, 2022, and June 10, 2022, were included in the study. Results: Of the 7,978 patients included in the study, 332 were excluded from further analyses because of pre-existing infection, and SAP compliance analyses were performed on the remaining 7,646 cases. The antibiotic most commonly used for SAP was cefazolin (n = 4,701; 61.5%), followed by third-generation cephalosporins (n = 596; 7.8%). The most common time to start SAP was within 30 minutes before surgery (n = 2,252; 32.5%), followed by 30 to 60 minutes before surgery (n = 1,638; 23.6%). Surgical antimicrobial prophylaxis duration was <24 hours in 3,516 (50.7%) patients and prolonged until discharge in 1,505 (21.7%) patients. Finally, the actual proportion of patients compliant with SAP was 19% (n = 1,452) after omitting 4,458 (58.3%) patients who were prescribed oral antibiotic agents at discharge as part of a prolonged SAP. Conclusions: Surgical antimicrobial prophylaxis compliance rates are still very low in Turkey. Prolonged duration of SAP and especially high rate of antibiotic prescription at discharge are the main reasons for non-compliance with SAP.
Collapse
Affiliation(s)
- Semiha Çelik Ekinci
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Ataşehir, İstanbul, Turkey
| | - Ercan Yenilmez
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Ataşehir, İstanbul, Turkey
| | - Gülfem Akengin Öcal
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey
| | - Meliha Çağla Sönmezer
- Department of Infectious Diseases and Clinical Microbiology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
| | - Arzu Tarakçı
- Department of Infectious Diseases and Clinical Microbiology, Konya City Hospital, Konya, Turkey
| | - Cemanur Aygün
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Samsun Training and Research Hospital, Samsun, Turkey
| | - Damla Akdağ
- Department of Infectious Diseases and Clinical Microbiology, Başakşehir Çam ve Sakura City Hospital, İstanbul, Turkey
| | - Derya Seyman
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey
| | - Cansu Aşık
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey
| | - Esra Zerdali
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Haseki Training and Research Hospital, İstanbul, Turkey
| | - Fatma Yılmaz Karadağ
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey
| | - Şafak Kaya
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey
| | - Mehmet Çelik
- Department of Infectious Diseases and Clinical Microbiology, Harran University, Faculty of Medicine, Şanlıurfa, Turkey
| | - Şeyma Çifci
- Department of Infectious Diseases and Clinical Microbiology, Nevşehir State Hospital, Nevşehir, Turkey
| | - İlknur Esen Yıldız
- Department of Infectious Diseases and Clinical Microbiology, Recep Tayyip Erdoğan University, Faculty of Medicine, Rize, Turkey
| | - Fatma Çölkesen
- Department of Infectious Diseases and Clinical Microbiology, Konya Numune Hospital, Konya, Turkey
| | - Fethiye Akgül
- Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, Batman, Turkey
| | - Özlem Aldemir
- Department of Infectious Diseases and Clinical Microbiology, Sivas Numune Hospital, Sivas, Turkey
| | - Merve Bozdağ
- Department of Infectious Diseases and Clinical Microbiology University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Deniz Özer
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
| | - Lokman Hızmalı
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kırşehir Ahi Evran University, Kırşehir, Turkey
| | - Esra Canbolat Ünlü
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey
| | - Deniz Gür Altunay
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Van Training and Research Hospital, Van, Turkey
| | - Ahmet Şahin
- Department of Infectious Diseases and Clinical Microbiology, Gaziantep Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - Gülten Ünlü
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey
| | - Ayşe Eda Gençalioğlu
- Department of Infectious Diseases and Clinical Microbiology, Trabzon Fatih State Hospital, Trabzon, Turkey
| | - Sema Tekin Şahin
- Department of Infectious Diseases and Clinical Microbiology, Alanya Training and Research Hospital, Antalya, Turkey
| | - Yeliz Özdemir
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bozyaka Training and Research Hospital, İzmir, Turkey
| | - Sibel Ünlü
- Department of Infectious Diseases and Clinical Microbiology, Mersin Toros State Hospital, Mersin, Turkey
| | - Sarp Singil
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Jale Altıntaş
- Department of Infectious Diseases and Clinical Microbiology, Gebze Fatih State Hospital, Kocaeli, Turkey
| | - Sinem Akkaya Işık
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Sultan 2.Abdülhamid Han Training and Research Hospital, İstanbul, Turkey
| | - Özlem Gül
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey
| | - Nazan Tuna
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdağ, Turkey
| | - Sümeyra Şimşek
- Department of Infectious Diseases and Clinical Microbiology, Çorlu State Hospital, Tekirdağ, Turkey
| | - Müge Özgüler
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey
| | - Pınar Elbir Kılıç
- Department of Infectious Diseases and Clinical Microbiology, Tuzla State Hospital, İstanbul, Turkey
| | - Mehmet Emirhan Işık
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Koşuyolu High Specialization Education and Research Hospital, İstanbul, Turkey
| | - Ayşe Karakuş
- Department of Infectious Diseases and Clinical Microbiology, Hendek State Hospital, Sakarya, Turkey
| | - Kazım Kıratlı
- Department of Infectious Diseases and Clinical Microbiology, Katip Çelebi University, İzmir Atatürk Training and Research Hospital, İzmir, Turkey
| | - Ahmet Cem Yardımcı
- Department of Infectious Diseases and Clinical Microbiology, VM Medical Park Mersin Hospital, Mersin, Turkey
| | - Serkan Volkan
- Department of Infectious Diseases and Clinical Microbiology, Aydın State Hospital, Aydın, Turkey
| | - Yıldız Olçar
- Department of Infectious Diseases and Clinical Microbiology, Kastamonu Training and Research Hospital, Kastamonu, Turkey
| | - Yasemin Çakır
- Department of Infectious Diseases and Clinical Microbiology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkey
| | - Nermin Özer Yılmaz
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Süreyyapaşa Chest Diseases and Thoracic Surgery Training And Research Hospital, İstanbul, Turkey
| | - Serhat Karaayvaz
- Department of Infectious Diseases and Clinical Microbiology, Ezine State Hospital, Çanakkale, Turkey
| | - Ayşe Batırel
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey
| | - Zeynep Cansu Duran
- Department of Infectious Diseases and Clinical Microbiology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
| | - Hüseyin Kemal Raşa
- Department of General Surgery, Anadolu Medical Center Gebze, Kocaeli, Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
| |
Collapse
|
4
|
Büyüktuna SA, Öksüz C, Tahmaz A, Sarıgül Yıldırım F, Türken M, Günal Ö, Topal Ş, Baran Aİ, Sarıkaya B, Çelik Ekinci S, Kaya S, Alkan Çeviker S, Aypak A, Yürük Atasoy P, İnan D, Köse A, Koç İnce N, Şenbayrak S, Kaya Ş, Özgüler M, Dindar Demiray EK, Köse Ş. [Distribution of the Prevalence of Human Leukocyte Antigen (HLA)-B*57:01 Positivity in HIV-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Group]. MIKROBIYOL BUL 2024; 58:29-38. [PMID: 38263938 DOI: 10.5578/mb.20249903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
Human immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of individuals in all age groups. The landscape of HIV infection has changed significantly in recent years due to the introduction of effective combination antiretroviral therapies (ART). A key component of first-line ART regimens for HIV treatment is abacavir, a nucleoside HIV reverse transcriptase inhibitor. Although abacavir is effective in suppressing viral replication and managing disease, its clinical utility is overshadowed by the potential for life-threatening hypersensitivity reactions in HLA-B*57:01-positive patients. In our country, local data obtained from various centers regarding the prevalence of HLA-B*57:01 in HIV-1-infected patients are available. In this study, it was aimed to determine the prevalence of the HLA-B*57:01 genotype in HIV-infected patients who were followed up and treated in many regions of our country. This retrospective study consists of the data of the patients aged 18 years and over diagnosed with HIV-1 infection between 01.01.2019 and 31.07.2022. Age, gender, place of birth, mode of transmission of the disease, death status, CD4+ T cell count and HIV RNA levels at the first clinical presentation, HLA-B*57:01 positivity, and the method used, clinical stage of the disease, virological response time with the treatment they received were recorded from the patient files. Data were collected from 16 centers and each center used different methods to detect HLA-B*57:01. These methods were sequence-specific oligonucleotide probe hybridization (SSOP), DNA sequence-based typing (SBT), single-specific primer-polymerase chain reaction (SSP-PCR), allele-specific PCR (AS-PCR) and quantitative PCR (Q-PCR). A total of 608 HIV-infected individuals, 523 males (86%) and 85 females (14%), were included in the study. The mean age of the patients was 36.9 ± 11.9 (18-73) years. The prevalence of HLA-B*57:01 allele was found to be 3.6% (22 patients). The number of CD4+ T lymphocytes in HLA-B*57:01 allele-positive patients was > 500/ mm3 in 10 patients (45.5%), while the number of CD4+ T lymphocytes in HLA-B*57:01 negative patients was > 500/mm3 in 216 patients (36.9%) (p> 0.05). Viral load at the time of diagnosis was found to be lower in patients with positive HLA-B*57:01 allele but it was not statistically significant (p> 0.05). Although different treatment algorithms were used in the centers following the patients, it was observed that the duration of virological response was shorter in HLA-B*57:01 positive patients (p= 0.006). Although the presence of the HLA-B*57:01 allele has a negative impact due to its association with hypersensitivity, it is likely to continue to attract interest due to its association with slower progression of HIV infection and reduced risk of developing AIDS. In addition, although the answer to the question of whether it is cost-effective to screen patients for HLA-B*57:01 before starting an abacavir-containing ART regimen for the treatment of HIV infection is being sought, it seems that HIV treatment guidelines will continue to recommend screening to identify patients at risk in this regard.
Collapse
Affiliation(s)
- Seyit Ali Büyüktuna
- Sivas Cumhuriyet University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Sivas, Türkiye
| | - Caner Öksüz
- Sivas State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Sivas, Türkiye
| | - Alper Tahmaz
- University of Health Sciences, Antalya Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Antalya, Türkiye
| | - Figen Sarıgül Yıldırım
- Antalya Life Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Antalya, Türkiye
| | - Melda Türken
- University of Health Sciences İzmir Faculty of Medicine, İzmir City Hospital, Clinic of Infectious Disease and Clinical Microbiology, İzmir, Türkiye
| | - Özgür Günal
- Samsun University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Samsun, Türkiye
| | - Şeyma Topal
- Samsun University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Samsun, Türkiye
| | - Ali İrfan Baran
- Van Yüzüncü Yıl University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Van, Türkiye
| | - Burak Sarıkaya
- University of Health Sciences, Sultan 2nd Abdulhamid Khan Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Türkiye
| | - Semiha Çelik Ekinci
- University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Türkiye
| | - Selçuk Kaya
- Çanakkale Onsekiz Mart University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Çanakkale, Türkiye
| | - Sevil Alkan Çeviker
- Çanakkale Onsekiz Mart University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Çanakkale, Türkiye
| | - Adalet Aypak
- University of Health Sciences, Ankara City Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Ankara, Türkiye
| | - Pınar Yürük Atasoy
- University of Health Sciences, Ankara City Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Ankara, Türkiye
| | - Dilara İnan
- Akdeniz University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Antalya, Türkiye
| | - Adem Köse
- İnönü University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Malatya, Türkiye
| | - Nevind Koç İnce
- Düzce University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Düzce, Türkiye
| | - Seniha Şenbayrak
- University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Türkiye
| | - Şafak Kaya
- University of Health Sciences, Gazi Yaşargil Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Diyarbakır, Türkiye
| | - Müge Özgüler
- University of Health Sciences Hamidiye Faculty of Medicine, Elazığ Fethi Sekin City Health Practice and Research Center, Clinic of Infectious Diseases and Clinical Microbiology, Elazığ, Türkiye
| | | | - Şükran Köse
- Dokuz Eylül University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Türkiye
| |
Collapse
|
5
|
Güleç RD, Arslan FD, Özyılmaz B, Yılmaz N, Hancı SY, Köse Ş. Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies. J Immunol Methods 2023; 523:113577. [PMID: 37865308 DOI: 10.1016/j.jim.2023.113577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 10/17/2023] [Accepted: 10/18/2023] [Indexed: 10/23/2023]
Abstract
OBJECTIVE We aimed to show the cross-reactivity that may occur between immunoglobulin (Ig) M antibodies that form against Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) and human leukocyte antigens (HLA). METHODS Complement-dependent cytotoxicity (CDC) cross-reactivity between serum samples of 57 patients with IgM positive CMV and/or EBV infections and T and B cells from 15 healthy donors were evaluated. Dithiothreitol was used to distinguish cross-reactivity caused by IgM antibodies from IgG. RESULTS The cross-reactivity ratio between pathogenic IgM antibodies with T cell of the 12th donor, and B cell of the 3rd, 4th, and 8th donors was significantly higher (p = 0.011, <0.001, <0.001 and 0.013, respectively). The ratio of B cell CDC cross-reactivity of all donors (26.4%) was higher than the ratio of T cell CDC cross-reactivity (5.2%) (p < 0.001). The ratio of T cell CDC cross-reactivity of sera containing both anti-CMV IgM and anti-EBV IgM antibodies was significantly higher than those of sera containing only anti-CMV IgM or only anti-EBV IgM antibodies (p = 0.002 and p < 0.001, respectively). There was no difference between B cell CDC cross-reactivity rates according to the presence of anti-CMV and/or anti-EBV IgM antibodies. CONCLUSION Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.
Collapse
Affiliation(s)
- Rasime Derya Güleç
- University of Health Sciences, Tepecik Training and Research Hospital, Tissue Typing Laboratory, İzmir, Turkey.
| | - Fatma Demet Arslan
- Faculty of Medicine, Bakırçay University, Department of Medical Biochemistry, İzmir, Turkey
| | - Berk Özyılmaz
- University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Genetics, İzmir, Turkey
| | - Nisel Yılmaz
- University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Microbiology, İzmir, Turkey
| | - Sevgi Yılmaz Hancı
- University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Microbiology, İzmir, Turkey
| | - Şükran Köse
- University of Health Sciences, Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey
| |
Collapse
|
6
|
Köse Ş, Dal T, Çetinkaya RA, Arı O, Yenilmez E, Temel EN, Çetin ES, Arabacı Ç, Büyüktuna SA, Hasbek M, Külahlıoğlu N, Müderris T, Kaynar T, Sarı T, Yalçın AN, Ak K, Yıldırım BT, Şahin M, Durmaz R. Molecular epidemiological investigation of carbapenem resistant Klebsiella pneumoniae isolated from intensive care unit patients of six geographical regions of Turkey. J Infect Dev Ctries 2023; 17:1446-1451. [PMID: 37956378 DOI: 10.3855/jidc.17651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 03/07/2023] [Indexed: 11/15/2023] Open
Abstract
INTRODUCTION Klebsiella pneumonia causes serious infections in hospitalized patients. In recent years, carbapenem-resistant infections increased in the world. The molecular epidemiological investigation of carbapenem-resistant K. pneumoniae isolates was aimed in this study. METHODOLOGY Fifty carbapenem-resistant K. pneumoniae isolates from six geographical regions of Turkey between September 2019-2020 were included in the study. The disk diffusion method was used for the antibiotic susceptibility testing. The microdilution confirmed colistin susceptibility. Genetic diversity was investigated by MLST (Multi-Locus Sequence Typing). RESULTS The resistance rates were as follows: 49 (98%) for meropenem, 47 (94%) imipenem, 50 (100%) ertapenem, 30 (60%) colistin and amoxicillin-clavulanate, 49 (98%) ceftriaxone, 48 (96%) cefepime, 50 (100%) piperacillin-tazobactam, 47 (94%) ciprofloxacin, 40 (80%) amikacin, 37 (74%) gentamicin. An isolate resistant to colistin by disk diffusion was found as susceptible to microdilution. ST 2096 was the most common (n:16) sequence type by MLST. ST 101 (n:7), ST14 (n:6), ST 147 and ST 15 (n:4), ST391 (n:3), ST 377 and ST16 (n:2), ST22, ST 307, ST 985, ST 336, ST 345, and ST 3681 (n:1) were classified in other isolates. In İstanbul and Ankara ST2096 was common. Among Turkey isolates, the most common clonal complexes (CC) were CC14 (n:26) and CC11 (n = 7). CONCLUSIONS In Turkey, a polyclonal population of CC14 throughout the country and inter-hospital spread were indicated. The use of molecular typing tools will highlight understanding the transmission dynamics.
Collapse
Affiliation(s)
- Şükran Köse
- Sağlık Bilimleri University Tepecik Training and Research Hospital, Infectious Diseases Clinical Microbiology, İzmir, Turkey
| | - Tuba Dal
- Ankara Yıldırım Beyazıt University Faculty of Medicine, Medical Microbiology, Ankara, Turkey
| | - Rıza Aytaç Çetinkaya
- Sağlık Bilimleri University Hamidiye Faculty of Medicine, Infectious Diseases and Clinical Microbiology, İstanbul, Turkey
| | - Oğuz Arı
- Ankara Yıldırım Beyazıt University, Central Research and Application Center, Ankara, Turkey
| | - Ercan Yenilmez
- Sağlık Bilimleri University Hamidiye Faculty of Medicine, Infectious Diseases and Clinical Microbiology, İstanbul, Turkey
| | - Esra Nurlu Temel
- Süleyman Demirel University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Isparta, Turkey
| | - Emel Sesli Çetin
- Süleyman Demirel University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Isparta, Turkey
| | - Çiğdem Arabacı
- Sağlık Bilimleri University Okmeydanı Training and Research Hospital, Medical Microbiology, İstanbul, Turkey
| | - Seyit Ali Büyüktuna
- Cumhuriyet University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Sivas, Turkey
| | - Mürşit Hasbek
- Cumhuriyet University Faculty of Medicine, Medical Microbiology, Sivas, Turkey
| | | | - Tuba Müderris
- İzmir Katip Çelebi University Faculty of Medicine, Medical Microbiology, İzmir, Turkey
| | - Teoman Kaynar
- Samsun Gazi State Hospital, Infectious Diseases and Clinical Microbiology, Samsun, Turkey
| | - Tuğba Sarı
- Pamukkale University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Denizli, Turkey
| | - Ata Nevzat Yalçın
- Akdeniz University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Antalya, Turkey
| | - Kenan Ak
- Cumhuriyet University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Sivas, Turkey
| | | | - Merve Şahin
- Ankara Yıldırım Beyazıt University, Faculty of Medicine, Ankara, Turkey
| | - Rıza Durmaz
- Ankara Yıldırım Beyazıt University Faculty of Medicine, Medical Microbiology, Ankara, Turkey
| |
Collapse
|
7
|
Özbilgin A, Tunalı V, Çavuş İ, Tetik AV, Dinç M, Yalçın T, Gündüz C, Beyaz M, Köse Ş. Visceral Leishmaniasis Caused by Leishmania Tropica. Acta Parasitol 2023; 68:699-704. [PMID: 37351773 DOI: 10.1007/s11686-023-00695-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 06/07/2023] [Indexed: 06/24/2023]
Abstract
PURPOSE In Turkey, the main causative agent of visceral leishmaniasis (VL) is Leishmania. infantum and the main causative agent of cutaneous leishmaniasis (CL) is Leishmania tropica. In this study, we aimed to discuss the possible mechanisms, clinical aspects, and threat of visceralizing L. tropica. METHODS This study includes seven cases of VL caused by L. tropica.Five patients were male (71%) and four were adults (57%). RESULTS All the VL patients complained of fever and splenomegaly. Fatigue, pancytopenia, and hepatomegaly were present in six patients each (86%), while weight loss and gastrointestinal system (GIS) symptoms were present in 5 patients (71%). CONCLUSIONS In this study, we have evaluated seven cases of visceralized L. tropica (VLT) in the context of the changing leishmaniasis epidemiology in Turkey. We have evaluated the possible mechanisms of visceralization; inter- and intraspecies genetic exchange with all the old world leishmaniasis agents present in the region, stress induced by inappropriate use of drugs, and possible ongoing adaptation mechanisms of Leishmania spp. The threat posed by VLT is significant as L. tropica is the most widespread and most common cause of leishmaniasis in Turkey. We do not know the vectorial capacity of the sand flies for the transmission of VLT strains or if these strains are in circulation in Turkey. Future studies should be carried out to investigate these issues as the transition of L. tropica from a mild disease-causing agent to a mortal one poses a significant public health concern for Turkey and Europe.
Collapse
Affiliation(s)
- Ahmet Özbilgin
- Department of Parasitology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey
| | - Varol Tunalı
- Department of Parasitology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.
- Department of Emergency Medicine, Eşrefpaşa Municipality Hospital, Yenişehir, Gaziler Cd No: 315, 35170, Konak/İzmir, Turkey.
| | - İbrahim Çavuş
- Department of Parasitology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey
| | - Aslı Vardarlı Tetik
- Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Melike Dinç
- Department of Chemistry, Izmir Institute of Technology, Izmir, Turkey
| | - Talat Yalçın
- Department of Chemistry, Izmir Institute of Technology, Izmir, Turkey
| | - Cumhur Gündüz
- Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Merve Beyaz
- Department of Chemistry, Izmir Institute of Technology, Izmir, Turkey
| | - Şükran Köse
- Department of Infectious Diseases, Dokuz Eylül University Faculty of Medicine, Izmir, Turkey
| |
Collapse
|
8
|
Uçar H, Yıldırım S, Köse Ş, Kirakli C. Incidence of nosocomial infection and causative microorganism during extracorporeal membrane oxygenation in adult patients, a single center study. Perfusion 2023:2676591231194931. [PMID: 37550246 DOI: 10.1177/02676591231194931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023]
Abstract
INTRODUCTION Extracorporeal membrane oxygenation (ECMO) is an organ support whose use is increasing in acute respiratory distress syndrome (ARDS) cases where adequate gas exchange cannot be achieved despite mechanical ventilation. Patients who were followed up on ECMO are at risk for developing nosocomial infections. In this study, we aimed to investigate the incidence of nosocomial infection and define isolated pathogens from microbiological samples in a single center in Turkey. METHODS Patients who were followed up on ECMO due to ARDS between January 1, 2018, and December 31, 2021, were included in the study. Nosocomial infections that were diagnosed after the first 48 h of ECMO cannulation and after 48 h of ECMO decannulation were accepted as ECMO-related infections. RESULTS A total of 50 patients with ARDS were followed up with ECMO. Mean age of patients was 46,8 ± 15,4 and 38 (78%) patients were male. A total of 30 patients (60%) had at least one nosocomial infection, for a rate of 37.6 per 1000 ECMO days. COVID-19, steroid treatment, and ECMO duration were found to be associated with nosocomial infections in patients who underwent ECMO support. In multivariate analysis, antibiotic use was found to be protective against nosocomial infection (OR:0.14, 95% CI: 0.03 - 0.70, p = .017). In addition, prolonged ECMO duration was associated with an increased risk of nosocomial infection in multivariate analysis (OR:1.13, 95% CI: 1.03 - 1.23, p = .010). Gram-negative pathogens were isolated dominantly in blood cultures and tracheal secretion samples, followed by fungi and Gram-positive bacteria. CONCLUSION Patients are prone to nosocomial infections during ECMO. Microorganisms causing nosocomial infections in ECMO patients seem similar to the flora of each center, and this should be taken into account in the choice of empirical antibiotics.
Collapse
Affiliation(s)
- Hüseyin Uçar
- Department of Intensive Care Unit, İzmir School of Medicine, Dr Suat Seren Chest Disease and Surgery Training and Research Hospital, University of Health Sciences Turkey, İzmir, Turkey
| | - Süleyman Yıldırım
- Department of Intensive Care Unit, İzmir School of Medicine, Dr Suat Seren Chest Disease and Surgery Training and Research Hospital, University of Health Sciences Turkey, İzmir, Turkey
| | - Şükran Köse
- Department of Infectious Disease and Clinical Microbiology, İzmir School of Medicine, İzmir Tepecik Training and Research Hospital, University of Health Sciences, İzmir, Turkey
| | - Cenk Kirakli
- Department of Intensive Care Unit, İzmir School of Medicine, Dr Suat Seren Chest Disease and Surgery Training and Research Hospital, University of Health Sciences Turkey, İzmir, Turkey
| |
Collapse
|
9
|
Bafandeh S, Khodadadi E, Ganbarov K, Asgharzadeh M, Köse Ş, Samadi Kafil H. Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases. Evid Based Complement Alternat Med 2023; 2023:5525165. [PMID: 37096202 PMCID: PMC10122587 DOI: 10.1155/2023/5525165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 03/19/2023] [Accepted: 03/24/2023] [Indexed: 04/26/2023]
Abstract
Background A global pandemic has recently been observed due to the new coronavirus disease, caused by SARS-CoV-2. Since there are currently no antiviral medicines to combat the highly contagious and lethal COVID-19 infection, identifying natural sources that can either be viricidal or boost the immune system and aid in the fight against the disease can be an essential therapeutic support. Methods This review was conducted based on published papers related to the herbal therapy of COVID-19 by search on databases including PubMed and Scopus with herbal, COVID-19, SARS-CoV-2, and therapy keywords. Results To combat this condition, people may benefit from the therapeutic properties of medicinal plants, such as increasing their immune system or providing an antiviral impact. As a result, SARS-CoV-2 infection death rates can be reduced. Various traditional medicinal plants and their bioactive components, such as COVID-19, are summarized in this article to assist in gathering and debating techniques for combating microbial diseases in general and boosting our immune system in particular. Conclusion The immune system benefits from natural products and many of these play a role in activating antibody creation, maturation of immune cells, and stimulation of innate and adaptive immune responses. The lack of particular antivirals for SARS-CoV-2 means that apitherapy might be a viable option for reducing the hazards associated with COVID-19 in the absence of specific antivirals.
Collapse
Affiliation(s)
- Soheila Bafandeh
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ehsaneh Khodadadi
- Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, USA
| | - Khudaverdi Ganbarov
- Research Laboratory of Microbiology and Virology, Baku State University, Baku, Azerbaijan
| | - Mohammad Asgharzadeh
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylül Üniversitesi, Izmir, Turkey
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
10
|
Bülbül H, Derviş Hakim G, Ceylan C, Aysin M, Köse Ş. What Is the Place of Intermediate Care Unit in Patients with COVID-19? A Single Center Experience. Int J Clin Pract 2023; 2023:8545431. [PMID: 37122395 PMCID: PMC10139809 DOI: 10.1155/2023/8545431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 02/26/2023] [Accepted: 03/23/2023] [Indexed: 05/02/2023] Open
Abstract
Introduction COVID-19 pandemic has led to an increased rate of intensive care unit (ICU) stays. Intermediate care units (IMCUs) are a useful resource for the management of patients with severe COVID-19 that do not require ICU admission. In this research, we aimed to determine survival outcomes and parameters predicting mortality in patients who have been admitted to IMCU. Materials and Methods Patients who were admitted to IMCU between April 2019 and January 2021 were analyzed retrospectively. Sociodemographics, clinical characteristics, and blood parameters on admission were compared between the patients who died in IMCU and the others. Blood parameters at discharge were compared between survived and deceased individuals. Survival analysis was performed via Kaplan-Meier analysis. Blood parameters predicting mortality were determined by univariate and multivariate Cox regression analysis. Results A total of 140 patients were included within the scope of this study. The median age was 72.5 years, and 77 (55%) of them were male and 63 (45%) of them were female. A total of 37 (26.4%) patients deceased in IMCU, and 40 patients (28.5%) were transferred to ICU. Higher platelet count (HR 3.454; 95% CI 1.383-8.625; p=0.008), procalcitonin levels (HR 3.083; 95% CI 1.158-8.206; p=0.024), and lower oxygen saturation (HR 4.121; 95% CI 2.018-8.414; p < 0.001) were associated with an increased risk of mortality in IMCU. At discharge from IMCU, higher procalcitonin levels (HR 2.809; 95% CI 1.216-6.487; p=0.016), lower platelet count (HR 2.269; 95% CI 1.012-5.085; p=0.047), and noninvasive mechanic ventilation requirement (HR 2.363; 95% CI 1.201-4.651; p=0.013) were associated with an increased risk of mortality. Median OS was found as 41 days. The overall survival rate was found 40% while the IMCU survival rate was 73.6%. Conclusions IMCU seems to have a positive effect on survival in patients with severe COVID-19 infection. Close monitoring of these parameters and early intervention may improve survival rates and outcomes.
Collapse
Affiliation(s)
- Hale Bülbül
- Hematology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey
| | - Gözde Derviş Hakim
- Gastroenterology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey
| | - Cengiz Ceylan
- Hematology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey
| | - Murat Aysin
- Public Health Department, İzmir Katip Çelebi University Atatürk Training and Research Hospital, Karabağlar, İzmir, Turkey
| | - Şükran Köse
- Infectious Diseases Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey
| |
Collapse
|
11
|
Ozma MA, Abbasi A, Asgharzadeh M, Pagliano P, Guarino A, Köse Ş, Samadi Kafil H. Antibiotic therapy for pan-drug-resistant infections. Infez Med 2022; 30:525-531. [PMID: 36482958 PMCID: PMC9715010 DOI: 10.53854/liim-3004-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 11/18/2022] [Indexed: 12/12/2022]
Abstract
Antibiotic resistance occurs when microorganisms resist the drugs used against the infection caused by them and neutralize their effects over time using various mechanisms. These mechanisms include preventing drug absorption, changing drug targets, drug inactivating, and using efflux pumps, which ultimately cause drug resistance, which is named pan-drug-resistant (PDR) infection if it is resistant to all antimicrobial agents. This type of drug resistance causes many problems in society and faces the health system with difficulties; therefore their treatment is crucial and encourages doctors to develop new drugs to treat them. PDR Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli are among the most significant resistant bacteria to many antimicrobial agents, and only a limited range of antibiotics, especially synergistically are effective on them. For the therapy of PDR A. baumannii, tigecycline in combination with colestimethate, imipenem, amikacin, and ampicillin-sulbactam are the most effective treatments. The utilization of β-lactamase inhibitors such as ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam has the most efficacy against PDR P. aeruginosa. The PDR K. pneumoniae has been treated in the last decades with tigecycline and colistin, but currently, nitrofurantoin, fosfomycin, and pivmecillinam seem to be the most effective agent for the therapy of PDR E. coli. While these drugs impressively struggle with PDR pathogens, due to the daily increase in antibiotic resistance in microorganisms worldwide, there is still an urgent need for the expansion of novel medicines and methods of combating resistance.
Collapse
Affiliation(s)
- Mahdi Asghari Ozma
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz,
Iran
| | - Amin Abbasi
- Department of Food Science and Technology, National Nutrition and Food Technology, Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran,
Iran
| | - Mohammad Asgharzadeh
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz,
Iran
| | | | - Amedeo Guarino
- Department of Public Health, University of Naples Federico II, Naples,
Italy
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, 9 Eylul University, İzmir,
Turkey
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,
Iran
| |
Collapse
|
12
|
Sarıgül Yıldırım F, Üser Ü, Didem Sarı N, Kurtaran B, Önlen Y, Şenateş E, Gündüz A, Zerdali E, Karsen H, Batırel A, Karaali R, Güner R, Yamazhan T, Köse Ş, Erben N, İnce N, Köksal İ, Çuvalcı Öztoprak N, Yörük G, Kömür S, Bal T, Kaya S, Bozkurt İ, Günal Ö, Esen Yıldız İ, İnan D, Barut Ş, Namıduru M, Tosun S, Türker K, Şener A, Hızel K, Baykam N, Duygu F, Bodur H, Can G, Gül HC, Sağmak Tartar A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F. In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turk J Gastroenterol 2022; 33:971-978. [PMID: 36415900 PMCID: PMC9797763 DOI: 10.5152/tjg.2022.21834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/09/2021] [Accepted: 01/12/2022] [Indexed: 11/23/2022]
Abstract
BACKGROUND People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. METHODS We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. RESULTS Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). CONCLUSION Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.
Collapse
Affiliation(s)
- Figen Sarıgül Yıldırım
- Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Ülkü Üser
- Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Nagehan Didem Sarı
- Department of Infectious Diseases, İstanbul Education Research Hospital, İstanbul, Turkey
| | - Behice Kurtaran
- Department of Infectious Diseases and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Turkey
| | - Yusuf Önlen
- Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University Faculty of Medicine, Hatay, Turkey
| | - Ebubekir Şenateş
- Department of Gastroenterology, Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey
| | - Alper Gündüz
- Department of Infectious Diseases, İstanbul Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey
| | - Esra Zerdali
- Department of Infectious Diseases, Haseki Education Research Hospital, İstanbul, Turkey
| | - Hasan Karsen
- Department of Infectious Diseases and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Turkey
| | - Ayşe Batırel
- Department of Infectious Diseases, İstanbul Doctor Lütfi Kırdar Kartal Training and Research Hospital, İstanbul, Turkey
| | - Rıdvan Karaali
- Department of Infectious Diseases and Clinical Microbiology, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
| | - Rahmet Güner
- Department of Infectious Diseases and Clinical Microbiology, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey
| | - Tansu Yamazhan
- Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, İzmir, Turkey
| | - Şükran Köse
- Department of Infectious Diseases, İzmir Tepecik Training and Research Hospital, İzmir, Turkey
| | - Nurettin Erben
- Department of Infectious Diseases and Clinical Microbiology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey
| | - Nevin İnce
- Department of Infectious Diseases and Clinical Microbiology, Düzce University Medical School, Düzce, Turkey
| | - İftihar Köksal
- Department of Infectious Diseases and Clinical Microbiology, Karadeniz Teknik University Faculty of Medicine, Trabzon, Turkey
| | - Nefise Çuvalcı Öztoprak
- Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Gülşen Yörük
- Department of Infectious Diseases, İstanbul Education Research Hospital, İstanbul, Turkey
| | - Süheyla Kömür
- Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University Faculty of Medicine, Hatay, Turkey
| | - Tayibe Bal
- Department of Gastroenterology, Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey
| | - Sibel Kaya
- Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
| | - İlkay Bozkurt
- Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
| | - Özgür Günal
- Department of Infectious Diseases, Samsun Education Research Hospital, Samsun, Turkey
| | - İlknur Esen Yıldız
- Department of Infectious Diseases and Clinical Microbiology, Recep Tayyip Erdoğan University Training and Research Hospital, Rize, Turkey
| | - Dilara İnan
- Department of Infectious Diseases and Clinical Microbiology, Akdeniz University Medical School, Antalya, Turkey
| | - Şener Barut
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University Medical Faculty, Tokat, Turkey
| | - Mustafa Namıduru
- Department of Infectious Diseases and Clinical Microbiology, Gaziantep University Medical Faculty, Gaziantep, Turkey
| | - Selma Tosun
- Department of Infectious Diseases and Clinical Microbiology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey
| | - Kamuran Türker
- Department of Infectious Diseases, İstanbul Bağcılar Training and Research Hospital, İstanbul, Turkey
| | - Alper Şener
- Department of Infectious Diseases and Clinical Microbiology, Çanakkale 18 Mart University Faculty of Medicine, Çanakkale, Turkey
| | - Kenan Hızel
- Department of Infectious Diseases and Clinical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Nurcan Baykam
- Department of Infectious Diseases and Clinical Microbiology, Hitit University Faculty of Medicine, Çorum, Turkey
| | - Fazilet Duygu
- Department of Infectious Diseases, Ankara Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Hürrem Bodur
- Department of Infectious Diseases, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Güray Can
- Department of Gastroenterology, Bolu İzzet Baysal University Medical Faculty, Bolu, Turkey
| | - Hanefi Cem Gül
- Department of Infectious Diseases, Health Science University Gülhane Faculty of Medicine, Ankara, Turkey
| | - Ayşe Sağmak Tartar
- Department of Infectious Diseases and Clinical Microbiology, Fırat University School of Medicine, Elazığ, Turkey
| | - Güven Çelebi
- Department of Infectious Diseases and Clinical Microbiology, Zonguldak Bülent Ecevit University Training and Research Hospital, Zonguldak, Turkey
| | - Mahmut Sünnetçioğlu
- Department of Infectious Diseases and Clinical Microbiology, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey
| | - Oğuz Karabay
- Department of Infectious Diseases and Clinical Microbiology, Sakarya University Training and Research Hospital, Sakarya, Turkey
| | - Hayat Kumbasar Karaosmanoğlu
- Department of Infectious Diseases, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey
| | - Fatma Sırmatel
- Department of Infectious Diseases and Clinical Microbiology, Bolu İzzet Baysal University Medical Faculty, Bolu, Turkey
| | - Fehmi Tabak
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University Medical Faculty, Tokat, Turkey
| |
Collapse
|
13
|
Önlen Y, Bal T, Çabalak M, Çuvalcı Öztoprak N, Didem Sarı N, Kurtaran B, Şenateş E, Gündüz A, Zerdali E, Karsen H, Batırel A, Karaali R, Güner R, Yamazhan T, Köse Ş, Erben N, İnce N, Köksal İ, Sarıgül Yıldırım F, Yörük G, Kömür S, Kaya S, Esen Ş, Günal Ö, Esen Yıldız İ, İnan D, Barut Ş, Namıduru M, Tosun S, Türker K, Şener A, Hızel K, Baykam N, Duygu F, Akıncı E, Can G, User Ü, Cem Gül H, Akbulut A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F. Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turk J Gastroenterol 2022; 33:862-873. [PMID: 35946896 PMCID: PMC9623221 DOI: 10.5152/tjg.2022.21271] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 01/30/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. METHODS In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. RESULTS The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). CONCLUSION Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
Collapse
Affiliation(s)
- Yusuf Önlen
- Mustafa Kemal University Faculty of Medicine, Antakya, Turkey
| | - Tayibe Bal
- Mustafa Kemal University Faculty of Medicine, Antakya, Turkey
| | - Mehmet Çabalak
- Mustafa Kemal University Faculty of Medicine, Antakya, Turkey
| | | | | | | | - Ebubekir Şenateş
- Department of Gastroenterology, Medeniyet University Faculty of Medicine, İstanbul, Turkey
| | - Alper Gündüz
- Department of Infectious Diseases, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey
| | - Esra Zerdali
- Department of Infectious Diseases, Haseki Training and Research Hospital, İstanbul, Turkey
| | - Hasan Karsen
- Department of Infectious Diseases and Clinical Microbiology, Harran University Faculty of Medicine, Urfa, Turkey
| | - Ayşe Batırel
- Department of Infectious Diseases, Kartal Training and Research Hospital, İstanbul, Turkey
| | - Rıdvan Karaali
- Department of Infectious Diseases and Clinical Microbiology, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
| | - Rahmet Güner
- Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey
| | - Tansu Yamazhan
- Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, İzmir, Turkey
| | - Şükran Köse
- Department of Infectious Diseases, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Nurettin Erben
- Department of Infectious Diseases and Clinical Microbiology, Eskişehir Osman Gazi University, Eskişehir, Turkey
| | - Nevin İnce
- Department of Infectious Diseases and Clinical Microbiology, Düzce University Faculty of Medicine, Düzce, Turkey
| | - İftihar Köksal
- Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
| | - Figen Sarıgül Yıldırım
- Department of Infectious Diseases, Antalya Training and Research Hospital, Antalya, Turkey
| | - Gülşen Yörük
- Department of Infectious Diseases, İstanbul Training and Research Hospital, İstanbul, Turkey
| | - Süheyla Kömür
- Department of Infectious Diseases and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Turkey
| | - Sibel Kaya
- Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
| | - Şaban Esen
- Department of Infectious Diseases and Clinical Microbiology, Samsun 19 Mayıs University Faculty of Medicine, Samsun, Turkey
| | - Özgür Günal
- Department of Infectious Diseases, Samsun Training and Research Hospital, Samsun, Turkey
| | - İlknur Esen Yıldız
- Department of Infectious Diseases and Clinical Microbiology, RTE University Faculty of Medicine, Rize, Turkey
| | - Dilara İnan
- Department of Infectious Diseases and Clinical Microbiology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Şener Barut
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey
| | - Mustafa Namıduru
- Department of Infectious Diseases and Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Selma Tosun
- Department of Infectious Diseases, Bozyaka Training and Research Hospital, İzmir, Turkey
| | - Kamuran Türker
- Department of Infectious Diseases, Bağcılar Training and Research Hospital, İstanbul, Turkey
| | - Alper Şener
- Department of Infectious Diseases and Clinical Microbiology, Çanakkale 18 Mart University Faculty of Medicine, Çanakkale, Turkey
| | - Kenan Hızel
- Department of Infectious Diseases and Clinical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Nurcan Baykam
- Department of Infectious Diseases and Clinical Microbiology, Hitit University Faculty of Medicine, Çorum, Turkey
| | - Fazilet Duygu
- Department of Infectious Diseases, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Esragül Akıncı
- Department of Infectious Diseases, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Güray Can
- Department of Gastroenterology, Bolu İzzet Baysal University Faculty of Medicine, Bolu, Turkey
| | - Ülkü User
- Department of Infectious Diseases and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Turkey
| | - Hanefi Cem Gül
- Department of Infectious Diseases, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Ayhan Akbulut
- Department of Infectious Diseases and Clinical Microbiology, Fırat University Faculty of Medicine, Elazığ, Turkey
| | - Güven Çelebi
- Department of Infectious Diseases and Clinical Microbiology, Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
| | - Mahmut Sünnetçioğlu
- Department of Infectious Diseases and Clinical Microbiology, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey
| | - Oğuz Karabay
- Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Hatay, Turkey
| | | | - Fatma Sırmatel
- Department of Infectious Diseases and Clinical Microbiology, Bolu İzzet Baysal University Faculty of Medicine, Bolu, Turkey
| | - Fehmi Tabak
- İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty of Medicine, İstanbul, Turkey
| |
Collapse
|
14
|
İlgezdi İ, Şener U, Öcek L, Köse Ş, Sarıteke A, Tokuçoğlu F, Zorlu Y. Copeptin Levels In Clinical Silent Multiple Sclerosis. tnd 2022. [DOI: 10.4274/tnd.2022.95776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
15
|
Ozma MA, Abbasi A, Akrami S, Lahouty M, Shahbazi N, Ganbarov K, Pagliano P, Sabahi S, Köse Ş, Yousefi M, Dao S, Asgharzadeh M, Hosseini H, Kafil HS. Postbiotics as the key mediators of the gut microbiota-host interactions. Infez Med 2022; 30:180-193. [PMID: 35693065 PMCID: PMC9177191 DOI: 10.53854/liim-3002-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 05/10/2022] [Indexed: 06/15/2023]
Abstract
The priority of the Sustainable Development Goals for 2022 is to reduce all causes related to mortality. In this regard, microbial bioactive compounds with characteristics such as optimal compatibility and close interaction with the host immune system are considered a novel therapeutic approach. The fermentation process is one of the most well-known pathways involved in the natural synthesis of a diverse range of postbiotics. However, some postbiotics are a type of probiotic response behavior to environmental stimuli that usually play well-known biological roles. Also, postbiotics with unique structure and function are key mediators between intestinal microbiota and host cellular processes/metabolic pathways that play a significant role in maintaining homeostasis. By further understanding the nature of parent microbial cells, factors affecting their metabolic pathways, and the development of compatible extraction and identification methods, it is possible to achieve certain formulations of postbiotics with special efficiencies, which in turn will significantly improve the performance of health systems (especially in developing countries) toward a wide range of acute/chronic diseases. The present review aims to describe the fundamental role of postbiotics as the key mediators of the microbiota-host interactions. Besides, it presents the available current evidence regarding the interaction between postbiotics and host cells through potential cell receptors, stimulation/improvement of immune system function, and the enhancement of the composition and function of the human microbiome.
Collapse
Affiliation(s)
- Mahdi Asghari Ozma
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Amin Abbasi
- Student Research Committee, Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sousan Akrami
- Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Masoud Lahouty
- Department of Microbiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
| | - Nayyer Shahbazi
- Department of Food Science, Faculty of Agriculture Engineering, Shahrood University of Technology, Shahrood, Iran
| | - Khudaverdi Ganbarov
- Research Laboratory of Microbiology and Virology, Baku State University, Baku, Azerbaijan
| | | | - Sahar Sabahi
- Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Şükran Köse
- Izmir University of Health Sciences, Tepecik Research and Educational Hospital, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey
| | - Mehdi Yousefi
- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sounkalo Dao
- Faculté de Médecine, de Pharmacie et d’Odonto-Stomatologie (FMPOS), Infectious Disease Department, University of Bamako, Bamako, Mali
| | - Mohammad Asgharzadeh
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hedayat Hosseini
- Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
16
|
Köse Ş, Şamlıoğlu P, Derviş Hakim G, Yiğitaslan M, Somay R, Tatar B, Bozkurt M. Correlation of Rapid Antibody and RT-PCR Tests With Clinical and Radiological Findings in COVID-19 Patients Admitted to an Employee Health Outpatient Clinic. cjms 2022. [DOI: 10.4274/cjms.2021.2021-66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Tabak F, Şirin G, Demir M, Aladağ M, Sümer Ş, Kurtaran B, Tosun S, Yamazhan T, Bozkurt İ, Gürbüz Y, Batırel A, Şenateş E, Kandemir FÖ, Topal F, Doğanay HL, Sezgin O, Mıstık R, Köse Ş, Yılmaz Y, İnan D, Köksal İ, Parlak E, Akdoğan M, Güner R. Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial. Egypt J Immunol 2021. [DOI: 10.4274/vhd.galenos.2021.2021-1-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, Ganbarov K, Köse Ş, Yousefi M, Kafil HS. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. Int J Biol Macromol 2021; 188:740-750. [PMID: 34403674 PMCID: PMC8364403 DOI: 10.1016/j.ijbiomac.2021.08.076] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 08/07/2021] [Accepted: 08/10/2021] [Indexed: 12/24/2022]
Abstract
The world has been suffering from COVID-19 disease for more than a year, and it still has a high mortality rate. In addition to the need to minimize transmission of the virus through non-pharmacological measures such as the use of masks and social distance, many efforts are being made to develop a variety of vaccines to prevent the disease worldwide. So far, several vaccines have reached the final stages of safety and efficacy in various phases of clinical trials, and some, such as Moderna/NIAID and BioNTech/Pfizer, have reported very high safety and protection. The important point is that comparing different vaccines is not easy because there is no set standard for measuring neutralization. In this study, we have reviewed the common platforms of COVID-19 vaccines and tried to present the latest reports on the effectiveness of these vaccines.
Collapse
Affiliation(s)
- Hadis Fathizadeh
- Department of laboratory sciences, Sirjan School of Medical Sciences, Sirjan, Iran
| | - Saman Afshar
- Department of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran
| | - Mahmood Reza Masoudi
- Department of Internal Medicine, Sirjan School of Medical Sciences, Sirjan, Iran
| | - Pourya Gholizadeh
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Iran
| | | | | | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Mehdi Yousefi
- Stem Cell Research Center, Tabriz University of Medical Sciences, Iran.
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Iran.
| |
Collapse
|
19
|
Gholizadeh P, Aghazadeh M, Ghotaslou R, Ahangarzadeh Rezaee M, Pirzadeh T, Köse Ş, Ganbarov K, Yousefi M, Kafil HS. CRISPR- cas system in the acquisition of virulence genes in dental-root canal and hospital-acquired isolates of Enterococcus faecalis. Virulence 2021; 11:1257-1267. [PMID: 32930628 PMCID: PMC7549939 DOI: 10.1080/21505594.2020.1809329] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Enterococcus faecalis is one of the important causative agents of nosocomial and life-threatening infections in human. Several studies have demonstrated that the presence of CRISPR-cas is associated with antibiotic susceptibility and lack of virulence traits. In this study, we aimed to assess the phenotypic and genotypic virulence determinants in relation to CRISPR elements from the dental-root canals and hospital-acquired isolates of E. faecalis. Eighty-eight hospital-acquired and 73 dental-root canal isolates of E. faecalis were assessed in this study. Phenotypic screening of the isolates included biofilm formation, and gelatinase and hemolysis activities. Genotypical screening using PCR was further used to evaluate the presence of CRISPR elements and different virulence-associated genes such as efaA, esp, cylA, hyl, gelE, ace, ebpR, and asa1. Biofilm formation, gelatinase, and hemolysis activities were detected in 93.8%, 29.2%, and 19.2% of the isolates, respectively. The most prevalent virulence-associated gene was ace, which was followed by efaA, whereas cylA was the least identified. The presence of CRISPR1-cas, orphan CRISPR2, and CRISPR3-cas was determined in 13%, 55.3%, and 17.4% of the isolates, respectively. CRISPR elements were significantly more prevalent in the dental-root canal isolates. An inverse significant correlation was found between CRISPR-cas loci, esp, and gelE, while direct correlations were observed in the case of cylA, hyl, gelE (among CRISPR-loci 1 and 3), asa1, ace, biofilm formation, and hemolysis activity. Findings, therefore, indicate that CRISPR-cas might prevent the acquisition of some respective pathogenicity factors in some isolates, though not all; so selective forces could not influence pathogenic traits. Abbreviations: BHI: brain-heart infusion agar; CRISPRs: Clustered regularly interspaced short palindromic repeats; Esp: Cell wall-associated protein; ENT: ear-nose-throat; ICU: intensive care units; OD: optical densities; PCR: polymerase chain reaction; SDS: sodium dodecyl sulfate; UTI: urinary tract infection
Collapse
Affiliation(s)
- Pourya Gholizadeh
- Drug Applied Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| | - Mohammad Aghazadeh
- Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| | - Reza Ghotaslou
- Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| | | | - Tahereh Pirzadeh
- Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital , İzmir, Turkey
| | | | - Mehdi Yousefi
- Biotechnology Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran.,Stem Cell Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences , Tabriz, I.R. Iran
| |
Collapse
|
20
|
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, Pullukçu H, Batum Ö, Şimşek Yavuz S, Turhan Ö, Yıldırmak MT, Köksal İ, Taşova Y, Korten V, Yılmaz G, Çelen MK, Altın S, Çelik İ, Bayındır Y, Karaoğlan İ, Yılmaz A, Özkul A, Gür H, Unal S. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398:213-222. [PMID: 34246358 PMCID: PMC8266301 DOI: 10.1016/s0140-6736(21)01429-x] [Citation(s) in RCA: 559] [Impact Index Per Article: 186.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 06/10/2021] [Accepted: 06/15/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. METHODS This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 μg inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0·5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. FINDINGS Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65·1%] in the vaccine group and 3568 [34·9%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 [65·4%] and 3470 [34·6%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36-48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (31·7 cases [14·6-59·3] per 1000 person-years) and 32 cases were reported in the placebo group (192·3 cases [135·7-261·1] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4-92·1; p<0·0001). The frequencies of any adverse events were 1259 (18·9%) in the vaccine group and 603 (16·9%) in the placebo group (p=0·0108) with no fatalities or grade 4 adverse events. The most common systemic adverse event was fatigue (546 [8·2%] participants in the vaccine group and 248 [7·0%] the placebo group, p=0·0228). Injection-site pain was the most frequent local adverse event (157 [2·4%] in the vaccine group and 40 [1·1%] in the placebo group, p<0·0001). INTERPRETATION CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile. FUNDING Turkish Health Institutes Association.
Collapse
Affiliation(s)
- Mine Durusu Tanriover
- Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey
| | - Hamdi Levent Doğanay
- Department of Gastroenterology, Turkish Republic Ministry of Health, İstanbul Provincial Health Directorate, University of Health Sciences İstanbul Ümraniye Training and Research Hospital, İstanbul, Turkey
| | - Murat Akova
- Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey.
| | - Hatice Rahmet Güner
- Department of Infectious Diseases and Clinical Microbiology, Ankara Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey
| | - Alpay Azap
- Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
| | - Sıla Akhan
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University School of Medicine, Kocaeli, Turkey
| | - Şükran Köse
- Department of Infectious Diseases, Turkish Republic Ministry of Health, İzmir Provincial Health Directorate, İzmir University of Health Sciences Tepecik Training and Research Hospital, İzmir, Turkey
| | - Fatma Şebnem Erdinç
- Department of Infectious Diseases, Turkish Republic Ministry of Health, Ankara Provincial Health Directorate, Ankara Training and Research Hospital, Ankara, Turkey
| | - Emin Halis Akalın
- Department of Infectious Diseases and Clinical Microbiology, Bursa Uludağ University Health Application and Research Centre, Bursa Uludağ University Hospital, Bursa, Turkey
| | - Ömer Fehmi Tabak
- Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey
| | - Hüsnü Pullukçu
- Department of Infectious Diseases and Clinical Microbiology, Ege University School of Medicine, İzmir, Turkey
| | - Özgür Batum
- Department of Chest Diseases, Turkish Republic Ministry of Health, İzmir Provincial Health Directorate, University of Health Sciences Dr Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Serap Şimşek Yavuz
- Department of Infectious Diseases and Clinical Microbiology, İstanbul University, İstanbul School of Medicine, İstanbul, Turkey
| | - Özge Turhan
- Department of Infectious Diseases and Clinical Microbiology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Mustafa Taner Yıldırmak
- Department of Infectious Diseases and Clinical Microbiology, Turkish Republic Ministry of Health, İstanbul Provincial Health Directorate, Prof Dr Cemil Taşcıoğlu City Hospital, İstanbul, Turkey
| | - İftihar Köksal
- Department of Infectious Diseases and Clinical Microbiology, Acıbadem University Atakent Hospital, İstanbul, Turkey
| | - Yeşim Taşova
- Department of Infectious Diseases and Clinical Microbiology, Çukurova University Balcalı Hospital Health Application and Research Centre, Adana, Turkey
| | - Volkan Korten
- Department of Infectious Diseases and Clinical Microbiology, Marmara University School of Medicine, İstanbul, Turkey
| | - Gürdal Yılmaz
- Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University School of Medicine, Trabzon, Turkey; Department of Chest Diseases, Turkish Republic Ministry of Health, Ankara Provincial Health Directorate, Ankara Keçiören Sanatorium, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
| | - Mustafa Kemal Çelen
- Department of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakır, Turkey
| | - Sedat Altın
- Department of Chest Diseases, Turkish Republic Ministry of Health, İstanbul Provincial Health Directorate, University of Health Sciences İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey
| | - İlhami Çelik
- Department of Infectious Diseases and Clinical Microbiology, Turkish Republic Ministry of Health, Kayseri City Training and Research Hospital, Kayseri, Turkey
| | - Yaşar Bayındır
- Department of Infectious Diseases and Clinical Microbiology, İnönü University Turgut Özal Health Centre, Malatya, Turkey
| | - İlkay Karaoğlan
- Department of Infectious Diseases and Clinical Microbiology, Gaziantep University Şahinbey Research and Application Centre, Gaziantep, Turkey
| | - Aydın Yılmaz
- Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University School of Medicine, Trabzon, Turkey; Department of Chest Diseases, Turkish Republic Ministry of Health, Ankara Provincial Health Directorate, Ankara Keçiören Sanatorium, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
| | - Aykut Özkul
- Department of Virology, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey
| | - Hazal Gür
- Department of Medical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Serhat Unal
- Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey
| |
Collapse
|
21
|
Asadi Faezi N, Gholizadeh P, Sanogo M, Oumarou A, Mohamed MN, Cissoko Y, Saliou Sow M, Keita BS, Baye YAM, Pagliano P, Akouda P, Soufiane S, Iknane AA, Safiatou Diallo MO, Gansane Z, Ali Khan B, Köse Ş, Allahverdipour H, Ganvarov K, Soumaré M, Asgharzadeh M, Dao S, Samadi Kafil H. Peoples' attitude toward COVID-19 vaccine, acceptance, and social trust among African and Middle East countries. Health Promot Perspect 2021; 11:171-178. [PMID: 34195040 PMCID: PMC8233680 DOI: 10.34172/hpp.2021.21] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 05/08/2021] [Indexed: 12/13/2022] Open
Abstract
Background: To end the COVID-19 pandemic, a large part of the world must be immune to the virus by vaccination. Therefore, this study aimed to gauge intent to be vaccinated against COVID-19 among ordinary people and to identify attitudes towards vaccines and barriers for vaccine acceptance. Methods: The study population comprises 1880 people residing in different countries that answer a prepared questionnaire. The questionnaire topics are demographics, historical issues, participants’ attitudes and beliefs regarding vaccines, concerns, and vaccine hesitancy. Results: Attitudes and beliefs relating to vaccines in general, and the COVID-19 vaccine, were ascertained. Overall, 66.81% of the contributors would like to be vaccinated against COVID-19, while %33.19 did not intend to be vaccinated. Reasons for COVID-19 vaccine hesitancy included concern regarding vaccine side effects, fear of getting sick from the uptake of the vaccine, and the absence of accurate vaccine promotion news. Individuals with higher education believe that India (68.6%) produces the best vaccine (P <0.001), while healthcare workers think the Chinese vaccine (44.2%) is the best (P =0.020). Individuals with higher education have not been vaccinated, not be healthcare workers, and females were the most contributors to effective of the vaccine in reducing mortality from COVID-19 disease. Conclusion: Given the degree of hesitancy against COVID-19 vaccination, a multifaceted approach to facilitate vaccine uptake that includes vaccine education, behavioral change strategies, and health promotion, is paramount.
Collapse
Affiliation(s)
- Nasim Asadi Faezi
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Pourya Gholizadeh
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Moussa Sanogo
- Faculty of Pharmacy USTTB, Faculty of Medicine and Odonto Stomatology, University of Science, Technics and Technology of Bamako, Bamako, Mali
| | - Amadou Oumarou
- Faculte des sciences la santé de l universite Dan Dicko DanKoulodo de Maradi, Niger
| | - Maad Nasser Mohamed
- Service des maladies infectieuses et tropicales de l'hôpital général peltier, Djibouti
| | - Yacouba Cissoko
- Faculty of Medicine and Odonto Stomatology (FMOS), USTTB, University of Science, Technics and Technology of Bamako, Bamako, Mali
| | - Mamadou Saliou Sow
- Service des Maladies Infectieuses, Hôpital National Donka, CHU Conakry, Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Guinea
| | - Bakary Sayon Keita
- Department of Medicine and Medical Specialities/Infectious Disease Unit of Fousseyni Daou Hospital, Kayes, Mali
| | - Youssouf Ag Mohamed Baye
- Faculty of Medicine and Odonto Stomatology (FMOS), USTTB, University of Science, Technics and Technology of Bamako, Bamako, Mali.,Department of Medicine and Medical Specialities/Infectious Disease Unit of Fousseyni Daou Hospital, Kayes, Mali
| | | | | | | | - Akory Ag Iknane
- Faculty of Medicine and Odonto Stomatology (FMOS), USTTB, University of Science, Technics and Technology of Bamako, Bamako, Mali.,Institut National de Santé Publique, Bamako, Mali
| | - Mamadou Oury Safiatou Diallo
- Service des Maladies Infectieuses, Hôpital National Donka, CHU Conakry, Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Guinea
| | - Zakaria Gansane
- Burkinabé Observatory for Healthcare Quality and Safety, Ouagadougou, Burkina Faso
| | - Barkat Ali Khan
- Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Hamid Allahverdipour
- Research Center of Psychiatry and Behavioural Sciences and Department of Health Education and Promotion, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | - Mariam Soumaré
- Faculty of Medicine and Odonto Stomatology (FMOS), USTTB, University of Science, Technics and Technology of Bamako, Bamako, Mali
| | - Mohammad Asgharzadeh
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sounkalo Dao
- Faculty of Medicine and Odonto Stomatology (FMOS), USTTB, University of Science, Technics and Technology of Bamako, Bamako, Mali
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
22
|
Akkaya Işık S, Seyman D, Zerdali E, Ayan S, Kakaliçoğlu D, Ayaz T, Canbolat Ünlü E, Çetinkaya RA, Yenilmez E, Görenek L, Köse Ş. Evaluation of 170 Followed-up Cases Treated for Hydatid Disease: A Multicentre Study. Turkiye Parazitol Derg 2021; 44:197-202. [PMID: 33269559 DOI: 10.4274/tpd.galenos.2020.6737] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Objective To determine the clinical characteristics of patients with cystic echinococcosis and the diagnostic and therapeutic approaches used. Methods This is a multicentre, retrospective study. Patients from six centres who were diagnosed with hydatid cysts in the last five years were evaluated. Results The mean age was 45.4±17.4 years, and 54.7% were female. The most common complaints were abdominal pain, nausea and vomiting, and the most common physical examination finding was abdominal tenderness. Most patients were diagnosed within 2-6 months. Anaemia and eosinophilia were the most common laboratory findings. The liver was the most commonly involved organ (n=153, 90%). One hundred twenty-five (73.5%) patients underwent ultrasonography. The largest cyst was present in the liver at stage four, and its diameter was 160x170 mm. The rates of the negative, grey zone and positive results were 9.4%, 8.8% and 81.8%. Surgery was more common (n=72, 42.4%) than puncture, aspiration, injection, and re-aspiration treatments (n=14, 8.2%). Of the 47 patients who had a recurrence, 22 (46.8%) had a history of hydatid cyst treatment. Conclusion Hydatid disease, which is endemic in our country, is diagnosed at a late stage. In terms of disease diagnosis, serological tests may be misleading. It was not possible to compare the success rates according to the treatment choices because of the lack of randomisation of stages and sizes of the lesions.
Collapse
Affiliation(s)
- Sinem Akkaya Işık
- Sağlık Bilimleri Üniversitesi, Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Derya Seyman
- Sağlık Bilimleri Üniversitesi, Antalya Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Antalya, Türkiye
| | - Esra Zerdali
- Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Saliha Ayan
- Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Deniz Kakaliçoğlu
- Sağlık Bilimleri Üniversitesi, Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Tunahan Ayaz
- Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye
| | - Esra Canbolat Ünlü
- Sağlık Bilimleri Üniversitesi, Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Rıza Aytaç Çetinkaya
- Sağlık Bilimleri Üniversitesi, Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Ercan Yenilmez
- Sağlık Bilimleri Üniversitesi, Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Levent Görenek
- Sağlık Bilimleri Üniversitesi, Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
| | - Şükran Köse
- Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniğis, İzmir, Türkiye
| |
Collapse
|
23
|
Gholizadeh P, Sanogo M, Oumarou A, Mohamed MN, Cissoko Y, Saliou Sow M, Pagliano P, Akouda P, Soufiane S, Iknane AA, Oury M, Diallo S, Köse Ş, Dao S, Samadi Kafil H. Fighting COVID-19 in the West Africa after experiencing the Ebola epidemic. Health Promot Perspect 2021; 11:5-11. [PMID: 33758750 PMCID: PMC7967127 DOI: 10.34172/hpp.2021.02] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 12/22/2020] [Indexed: 12/24/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) dissemination occurred from December 2019 and quickly spread to all countries. Infected patients with COVID-19 have had a wide range of symptoms, ranging from mild to severe illness. The most mortality was observed in patients with underlying disease and over 45 years. World statistics have shown that the COVID-19 outbreak is most expanded in Middle Eastern, West Asian, European, North, and South American countries, and is least expanded in African countries. Therefore, the aim of the paper was the evaluation of six African countries including Mali, Mauritania, Niger, Guinea, Togo, and Djibouti to find why this disease is least expanded in African countries. Study was conducted by Questioner for countries health organizers to define their different aspect exposure and fight with COVID-19 including epidemiology, clinical aspects of the disease, case definitions, diagnosis laboratory confirmation, and referral of cases by the portal of entry, case management, and disease prevention in these countries. According to this opinion review, due to the low international flights and low domestic travel, the spread, and prevalence of COVID-19 was low and the return of the immigrants of these countries has caused the spread of COVID-19 among these countries. Experience, preparation, and impact of previous infections epidemic such as the Ebola virus epidemic would have beneficial, which have promoted certain reflexes among people that cause low dissemination in these countries.
Collapse
Affiliation(s)
- Pourya Gholizadeh
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.,Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Moussa Sanogo
- Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | - Amadou Oumarou
- Faculte des sciences la santé de l universite Dan Dicko DanKoulodo de Maradi, Niger
| | - Maad Nasser Mohamed
- Service des maladies infectieuses et tropicales de l'hôpital général peltier, Djibouti
| | - Yacouba Cissoko
- Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Mamadou Saliou Sow
- Service des Maladies Infectieuses, Hôpital National Donka, CHU Conakry, Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Guinea
| | | | | | | | - Akory Ag Iknane
- Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali.,Institut National de Santé Publique, Bamako, Mali
| | - Mamadou Oury
- Service des Maladies Infectieuses, Hôpital National Donka, CHU Conakry, Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Guinea
| | - Safiatou Diallo
- Service des Maladies Infectieuses, Hôpital National Donka, CHU Conakry, Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Guinea
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Sounkalo Dao
- Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
24
|
Hajiagha MN, Taghizadeh S, Asgharzadeh M, Dao S, Ganbarov K, Köse Ş, Kafil HS. Gut microbiota And Human Body Interactions; Its Impact on Health: a review. Curr Pharm Biotechnol 2021; 23:4-14. [PMID: 33397232 DOI: 10.2174/1389201022666210104115836] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 11/17/2020] [Accepted: 11/19/2020] [Indexed: 12/27/2022]
Abstract
Gut microbiota (GM) as an organ of the human body has a particular and autonomous function that related to it. This review aimed to investigate human intestinal and gut microbiota interaction and its impact on health. As a creation referable database about this dynamic and complex organ, several comprehensive projects are implemented by using culture-dependent (culturomics), culture independent methods (e.g metagenomics, mathematics model), and Gnotobiological together. This study was done by searching PubMed, Scopus and Google scholar database in the gut, health microbiota and interaction keywords. The first acquired microbiota during pregnancy or childbirth is colonized in the gut by using specific and non-specific mechanisms. That`s structure and shape reach relative stability with selection pressure along with host development until adulthood and keep its resilience against external or internal variables depending on the host genetics and negative feedback. Due to several research individuals have 2 functional group microbiota including the core (common between vast majorities human) and flexible (transient population) microbiome. The most important role of the GM in the human body can be summarized in three basic landscapes: metabolic, immune system, and gut-brain axis interaction. So that loss of microbial population balance will lead to disorder and disease.
Collapse
Affiliation(s)
| | - Sepehr Taghizadeh
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz. Iran
| | - Mohammad Asgharzadeh
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz. Iran
| | - Sounkalo Dao
- Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie (FMPOS), University of Bamako, Bamako. Mali
| | | | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir. Turkey
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz. Iran
| |
Collapse
|
25
|
Kış TT, Köse Ş, Yılmaz O, Kış M, Yurt F, Acar E, Bekiş R, Yılmaz C, Barış M, Diniz G, Tatar B, Tunçel A. Evaluation of 99mTechnetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis. Curr Med Imaging 2020; 17:781-789. [PMID: 33372880 DOI: 10.2174/1573405616666201229161850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 09/21/2020] [Accepted: 10/15/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Infective endocarditis (IE) is an infection of the heart's endocardial surface. In recent years, nuclear imaging methods have gained importance in the diagnosis of IE. The present study aims to investigate the imaging potential of 99mTc-labeled vancomycin (99mTc-Vancomycin) as a new agent that would enable the diagnosis of IE in its early stages when it is difficult to diagnose or has small vegetation in the experimental rat model. METHODS 99mTc-Vancomycin scintigraphy was evaluated for its accumulation in IE with Staphylococcus aureus performed in an experimental rat model. Serial planar scintigraphic and biodistribution analysis of infected vegetations are compared to rats with sterile vegetations. The heart was identified as an infected organ, the liver was identified as a non-infected organ and the heart/liver uptake ratio (T / NT ratio) was compared between infective endocarditis and sterile endocarditis groups. RESULTS Planar scintigrams (in vivo measurements) showed more uptake in the heart of rats in the infective endocarditis group compared to the uptake in the heart of rats in the sterile endocarditis group, but this difference was not statistically significant (p>0.05). From the ex vivo measurements, the 99mTc-Vancomycin heart uptake increased significantly (p = 0.016), liver uptake was significantly decreased (p = 0.045) and the T/NT ratio was significantly higher (p = 0.014) in the infective endocarditis group compared to the sterile endocarditis group. CONCLUSION In this experimental study, 99mTc-Vancomycin scintigraphy ensured the detection of ex vivo infected tissue in a rat model of IE. In addition, the absence of significant 99mTc-Vancomycin uptake in the sterile endocarditis group indicates that this agent targeted the infected tissue instead of the sterile inflammatory tissue. Finally, this agent should also be evaluated with animal- specific imaging devices.
Collapse
Affiliation(s)
- Tuba Tatlı Kış
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | - Osman Yılmaz
- Department of Laboratory Animals Science, Dokuz Eylul University School of Medicine, Izmir, Turkey
| | - Mehmet Kış
- Depertment of Cardiology, Ege University School of Medicine, Izmir, Turkey
| | - Fatma Yurt
- Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Izmir, Turkey
| | - Emine Acar
- Department of Nuclear Medicine, Katip Celebi University School of Medicine, Izmir, Turkey
| | - Recep Bekiş
- Department of Nuclear Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
| | | | - Mustafa Barış
- Department of Radiology, Dokuz Eylul University School of Medicine, Izmir, Turkey
| | - Gülden Diniz
- Department of Pathology, Izmir Democracy University, Izmir, Turkey
| | - Bengü Tatar
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | - Ayça Tunçel
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
26
|
Fathizadeh H, Taghizadeh S, Safari R, Khiabani SS, Babak B, Hamzavi F, Ganbarov K, Esposito S, Zeinalzadeh E, Dao S, Köse Ş, Kafil HS. Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with Covid-19. Microb Pathog 2020; 149:104556. [PMID: 33031898 PMCID: PMC7534876 DOI: 10.1016/j.micpath.2020.104556] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 09/25/2020] [Accepted: 09/30/2020] [Indexed: 12/11/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease, which started in Wuhan, Chin, has now become a public health challenge in most countries around the world. Proper preventive measures are necessary to prevent the spread of the virus to help control the pandemic. Because, SARS-CoV-2 is new, its transmission route has not been fully understood. In this study, we aimed to investigate the presence of SARS-CoV-2 in the sweat secretion of COVID-19 patients. Sweat specimens of 25 COVID- 19 patients were collected and tested for SARS-CoV-2 RNA by Real-time Polymerase Chain Reaction (RT-PCR) method. After RNA extraction and cDNA amplification, all samples were examined for the presence of ORF-1ab and N genes related to COVID-19. Results annotated by Realtime PCR machines software based on Dynamic algorithm. The results of this study showed the absence of SARS-CoV-2 in the sweat samples taken from the foreheads of infected people. Therefore, it can be concluded that the sweat of patients with COVID- 19 cannot transmit SARS-CoV-2. However they can be easily contaminated with other body liquids.
Collapse
Affiliation(s)
- Hadis Fathizadeh
- Department of Microbiology and Immunology, Kashan University of Medical Sciences, Kashan, Iran
| | - Sepehr Taghizadeh
- Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Rohollah Safari
- Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Saeid Shabestari Khiabani
- Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Bayaz Babak
- Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fatemeh Hamzavi
- Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | | | - Elham Zeinalzadeh
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sounkalo Dao
- Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
27
|
Çelik D, Tatar B, Köse Ş, Ödemiş İ. Evaluation of the diagnostic validity of noninvasive tests for predicting liver fibrosis stage in chronic hepatitis B patients. Acta Gastroenterol Belg 2020; 83:419-425. [PMID: 33094589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
BACKGROUND AND STUDY AIM The aim of this study was to evaluate the effectiveness of noninvasive tests in predicting liver fibrosis levels in chronic hepatitis B (CHB) patients. PATIENTS AND METHODS A total of 539 treatment naive patients aged 18 years and older with CHB who underwent liver biopsy were included. Patients with coinfections and comorbidities were excluded. Data were obtained retrospectively from patient' follow- up files. Liver biopsy was evaluated according to the Ishak scoring system. SPSS 22.0 program was used for statistical analysis. Diagnostic sensitivity of APRI, FIB-4, NLR, GPR, AAR, RPR, API, King's score, Fibro Q and MPV was determined for predicting ≥F2, ≥F3, ≥F4, ≥F5 groups. RESULTS The median age of the CHB patients was 41 ±11.57 / year and 49.2% of the patients were female. The distribution of fibrosis stages was : F0, 16.5% ; F1, 26.4% ; F2, 39.7% ; F3, 10.4% ; F4, 4.1% ; F5, 2.4% ; F6 0.4%. Age, AST, ALT, GGT, ALP, RDW, HBV DNA levels were significantly higher, platelet and albumin levels were significantly lower in the ≥F3 group. All noninvasive tests except NLR and AAR predicted ≥F3 adequately (AUROC >0.5). King's score for predicting ≥F2, ≥F5, and GPR for predicting ≥F3 had the highest diagnostic power. The tests predicted the fibrosis stage better, as the fibrosis stage progressed. CONCLUSION As a result, most of the noninvasive tests we evaluated could predict significant fibrosis and cirrhosis with significant accuracy. The rate of unnecessary biopsies can be reduced with the help of these noninvasive tests.
Collapse
Affiliation(s)
- D Çelik
- Çigli Education and Research Hospital, Izmir, Turkey
| | - B Tatar
- Çigli Education and Research Hospital, Izmir, Turkey
| | - Ş Köse
- Çigli Education and Research Hospital, Izmir, Turkey
| | - İ Ödemiş
- Baskent University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Adana, Turkey
| |
Collapse
|
28
|
Özkaya H, Balcı N, Özkan Özdemir H, Demirdal T, Tosun S, Köse Ş, Yapar N. Treatment cost of HIV/AIDS in Turkey. IJHG 2020. [DOI: 10.1108/ijhg-01-2020-0003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PurposeThe purpose of this study is to estimate the average cost of treatment and investigate the related parameters of HIV/AIDS among patients based on their annual treatment regime during the 2017 in Izmir.Design/methodology/approachThe average annual direct cost of an HIV patient's treatment was estimated for 2017 at four university hospitals in a retrospective study in Izmir, Turkey. Inclusion criteria included confirmed HIV infection, age = 18 years, visited one of the hospitals at least three times a year and with at least one CD4+ T cell count. The average annual treatment cost per patient was calculated using accounting data for 527 patients from the hospitals' electronic databases.FindingsThe mean treatment cost per patient was US$4,381.93. Costs for treatment and care were statistically significantly higher (US$5,970.55) for patients with CD4+ T cell counts of fewer than 200 cells/mm3 than for other patients with CD4+ T cell counts above 200 cells/mm3. The mean treatment cost for patients who were 50 years old or older (US$4,904.24) was statistically significantly higher than for those younger than 50 years (US$4,216.10). The mean treatment cost for female patients (US$4,624.92) was higher than that of male patients ($US4,339.72), although the difference was not statistically significant. The main cost driver was antiretroviral treatment (US$3,852.38 per patient), accounting for almost 88% of all costs. However, the high burden of antiretroviral treatment cost is counterbalanced by relatively low care and hospitalization costs in Turkey.Originality/valueThe paper contributes to the literature by providing average annual treatment cost of an HIV-infected patient in Turkey by using a comprehensive bottom up approach. Moreover, cost drivers of HIV treatment are investigated.
Collapse
|
29
|
Gholizadeh P, Köse Ş, Dao S, Ganbarov K, Tanomand A, Dal T, Aghazadeh M, Ghotaslou R, Ahangarzadeh Rezaee M, Yousefi B, Samadi Kafil H. How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance. Infect Drug Resist 2020; 13:1111-1121. [PMID: 32368102 PMCID: PMC7182461 DOI: 10.2147/idr.s247271] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 03/31/2020] [Indexed: 12/26/2022] Open
Abstract
Rapid emergence of antibiotic-resistant bacteria has made it harder for us to combat infectious diseases and to develop new antibiotics. The clustered regularly interspaced short palindromic repeats - CRISPR-associated (CRISPR-Cas) system, as a bacterial adaptive immune system, is recognized as one of the new strategies for controlling antibiotic-resistant strains. The programmable Cas nuclease of this system used against bacterial genomic sequences could be lethal or could help reduce resistance of bacteria to antibiotics. Therefore, this study aims to review using the CRISPR-Cas system to promote sensitizing bacteria to antibiotics. We envision that CRISPR-Cas approaches may open novel ways for the development of smart antibiotics, which could eliminate multidrug-resistant (MDR) pathogens and differentiate between beneficial and pathogenic microorganisms. These systems can be exploited to quantitatively and selectively eliminate individual bacterial strains based on a sequence-specific manner, creating opportunities in the treatment of MDR infections, the study of microbial consortia, and the control of industrial fermentation.
Collapse
Affiliation(s)
- Pourya Gholizadeh
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Sounkalo Dao
- Faculté de Médecine, de Pharmacie et d’Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | - Khudaverdi Ganbarov
- Department of Microbiology, Baku State University, Baku, Republic of Azerbaijan
| | - Asghar Tanomand
- Department of Basic Sciences, Maragheh University of Medical Sciences, Maragheh, Iran
| | - Tuba Dal
- Department of Clinical Microbiology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Mohammad Aghazadeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Reza Ghotaslou
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | - Bahman Yousefi
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hossein Samadi Kafil
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
30
|
Fathizadeh H, Maroufi P, Momen-Heravi M, Dao S, Köse Ş, Ganbarov K, Pagliano P, Esposito S, Kafil HS. Protection and disinfection policies against SARS-CoV-2 (COVID-19). Infez Med 2020; 28:185-191. [PMID: 32275260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
In late December 2019, reports from China of the incidence of pneumonia with unknown etiology were sent to the World Health Organization (WHO). Shortly afterwards, the cause of this disease was identified as the novel beta-coronavirus, SARS-CoV-2, and its genetic sequence was published on January 12, 2020. Human-to-human transmission via respiratory droplets and contact with aerosol infected surfaces are the major ways of transmitting this virus. Here we attempted to collect information on virus stability in the air and on surfaces and ways of preventing of SARS-CoV-2 spreading.
Collapse
Affiliation(s)
- Hadis Fathizadeh
- Department of Microbiology and immunology, Kashan University of Medical Sciences, Kashan, I.R. Iran
| | - Parham Maroufi
- Department of Orthopedy, School of Medicine, Tabriz University of Medical Scienences, Tabriz, Iran; Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | - Sounkalo Dao
- Faculté de Medecine, de Pharmacie et Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Khudaverdi Ganbarov
- Department of Microbiology, Baku State University, Baku, Republic of Azerbaijan
| | | | | | - Hossein Samadi Kafil
- Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
31
|
Ozma MA, Maroufi P, Khodadadi E, Köse Ş, Esposito I, Ganbarov K, Dao S, Esposito S, Dal T, Zeinalzadeh E, Kafil HS. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez Med 2020; 28:153-165. [PMID: 32275257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The novel coronavirus SARS-CoV-2 (Covid-19), spreading from Wuhan, China, is one of the causes of respiratory infections that can spread to other people through respiratory particles, and can cause symptoms such as fever, dry cough, shortness of breath, anorexia, fatigue and sore throat in infected patients. This review summarizes current strategies on the diagnosis. Additionally, treatments, infection prevention and control of the SARS-CoV-2 are addressed. In addition to the respiratory system, this virus can infect the digestive system, the urinary system and the haematological system, which causes to observe the virus in the stool, urine and blood samples in addition to throat sample. The SARS-CoV-2 causes changes in blood cells and factors and makes lung abnormalities in patients, which can be detected by serological, molecular, and radiological techniques by detecting these changes and injuries. Radiological and serological methods are the most preferred among the other methods and the radiological method is the most preferred one which can diagnose the infection quickly and accurately with fewer false-negatives, that can be effective in protecting the patient's life by initiating treatment and preventing the transmission of infection to other people.
Collapse
Affiliation(s)
- Mahdi Asghari Ozma
- Student Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Parham Maroufi
- Department of Orthopedy, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Connective tissues Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ehsaneh Khodadadi
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
| | | | - Khudaverdi Ganbarov
- Department of Microbiology, Baku State University, Baku, Republic of Azerbaijan
| | - Sounkalo Dao
- Faculte de Medecine, de Pharmacie et Odonto-Stomatologie (FMPOS), University of Bamako, Bamako, Mali
| | | | - Tuba Dal
- Department of Clinical Microbiology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Elham Zeinalzadeh
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hossein Samadi Kafil
- Drug Applied Research Center, Tabriz University of Medical Science, Tabriz, Iran
| |
Collapse
|
32
|
Tatar B, Köse Ş, Ergun NC, Turken M, Onlen Y, Yılmaz Y, Akhan S. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. ACTA ACUST UNITED AC 2020; 65:1470-1475. [PMID: 31994628 DOI: 10.1590/1806-9282.65.12.1470] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 07/29/2019] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice. METHODS Thirty-six patients who attended our clinic, were diagnosed with chronic hepatitis C (CHC), undergoing hemodialysis, and fulfilled the criteria of age >18 years, genotype 1 infection, with a detectable HCV RNA level were considered for the study. Patients with GT1a infection received OBV/PTV/r plus DSV plus RBV for 12 weeks; GT1b infected patients received this regimen without RBV for 12 weeks. RESULTS The study was conducted on 33 patients. The mean age was 52.30 ±13.77 years, and 70 % of them were male. By the fourth week of treatment, HCV RNA levels decreased below 15 IU/ml in all patients. Sustained virologic response (SVR) 12 rate was 100%. Nine patients had side effects during treatment. Of the patients with side effects, 89.9% were in group 1a and 11.1% in group 1b. CONCLUSION In this study, treatment with OBV/PTV/r and DSV with or without RBV resulted in high rates of sustained virologic response in HCV GT1-infected patients with end-stage renal disease (ESRD). SVR was achieved in all patients with few side effects.
Collapse
Affiliation(s)
- Bengu Tatar
- . Turkiye Cumhuriyeti Saglik Bakanlıgı, Izmir Tepecik Egitim ve Arastirma Hastanesi, Infectious Diseases and Clinical Microbiology, Izmır, Turkey
| | - Şükran Köse
- . Turkiye Cumhuriyeti Saglik Bakanlıgı, Izmir Tepecik Egitim ve Arastirma Hastanesi, Infectious Diseases and Clinical Microbiology, Izmır, Turkey
| | - Nadide Colak Ergun
- . Turkiye Cumhuriyeti Saglik Bakanlıgı, Izmir Tepecik Egitim ve Arastirma Hastanesi, Infectious Diseases and Clinical Microbiology, Izmır, Turkey
| | - Melda Turken
- . Turkiye Cumhuriyeti Saglik Bakanlıgı, Izmir Tepecik Egitim ve Arastirma Hastanesi, Infectious Diseases and Clinical Microbiology, Izmır, Turkey
| | - Yusuf Onlen
- . Mustafa Kemal Universitesi, Infectious Diseases and Clinical Microbiology, Hatay, Turkey
| | - Yusuf Yılmaz
- . Marmara Universitesi, Gastroenterology, Istanbul, Turkey
| | - Sıla Akhan
- . Kocaeli Universitesi, Infectious Diseases and Clinical Microbiology, Kocaeli, Turkey
| |
Collapse
|
33
|
Tatar B, Gül S, Köse Ş, Pala E. Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection. Turk Patoloji Derg 2020; 1:154-158. [PMID: 32149362 PMCID: PMC10511254 DOI: 10.5146/tjpath.2020.01478] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Accepted: 01/24/2020] [Indexed: 12/14/2022] Open
Abstract
OBJECTIVE The aim of this study to evaluate histopathological improvement and virological, serological and biochemical response rates in patients with chronic hepatitis B (CHB) who were treated with tenofovir disoproxil fumarate (TDF). MATERIAL AND METHOD A total of 91 nucleosid(t)e-naive CHB patients who received TDF were evaluated. Virological, serological and biochemical test results were assessed at baseline and every 12 weeks. Liver biopsy specimens were assessed according to the modified Ishak scoring. RESULTS The study was conducted on 52 patients. The mean age was 40±10 years and 40.4% were female. The mean follow-up period was 33±11 months. HBsAg seroclearance occurred in none of the patients. The serum level of HBV-DNA became undetectable in 94.2% of the patients. Mean histological activity index at baseline and on-treatment were 8.2±2.3 and 6.2±2.0 and the mean fibrosis scores were 2.65±1.3 and 2.33±1.1, respectively. CONCLUSION We determined that TDF therapy provided remarkably good HBV DNA suppression and biochemical response rates, but low seroconversion. Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.
Collapse
Affiliation(s)
- Bengü Tatar
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences ,Izmir Tepecik Education and Research Hospital, Izmir, Turkey
| | - Selma Gül
- Batman State Hospital, Batman, Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences ,Izmir Tepecik Education and Research Hospital, Izmir, Turkey
| | - Emel Pala
- Department of Pathology, University of Health Sciences, Izmir Tepecik Education and Research Hospital, Izmir, Turkey
| |
Collapse
|
34
|
Adar P, Köse Ş, Tatar B. Occult Hepatitis B in Hemodialysis Patients. Egypt J Immunol 2019. [DOI: 10.4274/vhd.galenos.2019.2018.0009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
35
|
Abstract
Hepatitis B virus (HBV) infections and sequelae present significant health problems worldwide. Two groups of medications are available for chronic HBV infection treatment: (1) interferons (IFNs) and (2) nucleos(t)ide analogues. This study aimed to evaluate entecavir (ETV) and tenofovir disoproxil fumarate (TDF) efficacies in chronic HBV patients, who achieved virological response during Peg-IFN treatment but did not sustain this response and relapsed a year after treatment end. In this study, 74 patients with chronic HBV infection who had virological responses to 180 μg/week Peg-IFNα-2a treatment were included; 38 (20 and 18 HBeAg positive and negative, respectively) of these patients were treated with 245 mg/day TDF, and 36 (20 and 16 HBeAg positive and negative, respectively) were treated with 0.5 mg/day ETV upon relapse after initial treatment discontinuation. In HBeAg-positive patients biochemical response rates were higher for TDF at weeks 96 and 144 (p = 0.044 and 0.019, respectively). However, biochemical response rates were similar for TDF and ETV in HBeAg-positive and HBeAg-negative groups at other weeks (p > 0.05). Virological and serological response rates were similar in patients treated with TDF and ETV in HBeAg-positive and HBeAg-negative groups (p > 0.05).
Collapse
Affiliation(s)
- Şükran Köse
- a Department of Infectious Diseases and Clinical Microbiology , Tepecik Training and Research Hospital , İzmir , Turkey
| | - Tuba Tatli Kiş
- a Department of Infectious Diseases and Clinical Microbiology , Tepecik Training and Research Hospital , İzmir , Turkey
| | - Sabri Atalay
- a Department of Infectious Diseases and Clinical Microbiology , Tepecik Training and Research Hospital , İzmir , Turkey
| |
Collapse
|
36
|
Ödemiş İ, Köse Ş, Akbulut İ, Albayrak H. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness. Rev Esp Quimioter 2019; 32:525-531. [PMID: 31642641 PMCID: PMC6913082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE The aims of this study are to determine the seroprevalence for measles, mumps, rubella, and varicella zoster virus (VZV) in a cohort of nursing students, to evaluate vaccination response rates of nonimmune students, and to calculate the cost of vaccinating students based on seroprevalence screening. METHODS A cross-sectional study was conducted August 2015-November 2016 among 326 healthy nursing students aged 14.1-18.1 years. Serum IgG antibodies were measured by ELISA. Results were analyzed by the Chi-square test; a p-value of < 0.05 was considered statistically significant. RESULTS The number of seropositive participants (%) was 308 (94.5%) for rubella, 295 (90.5%) for VZV, 244 (74.9%) for measles, and 219 (67.2%) for mumps. A significant correlation was found between measles IgG and age. A relationship was also observed between VZV IgG and kindergarten attendance. Response rates to measles, rubella, VZV, and mumps vaccination were 96%, 92.3%, 87.5%, 78.8%, respectively. The total cost of vaccination after IgG screening was less than vaccination without screening. CONCLUSIONS In this study, participants' immunity to measles and VZV was low. Prevaccination serological screening was cost-effectiveness method for preventing measles, mumps, rubella, and varicella infections. We believe that administering booster measles, mumps, and rubella (MMR) vaccine doses or developing a special MMR vaccination strategy for at-risk groups may prevent MMR outbreaks.
Collapse
Affiliation(s)
- İlker Ödemiş
- Nigde Omer Halisdemir University, Training and Research Hospital, Infectious Diseases and Clinical Microbiology Clinic, Nigde, Turkey,Correspondence: İlker ÖdemişAşagi Kayabasi mah. Nigde Omer Halisdemir Universitesi, Egitim ve Arastirma Hastanesi Intaniye Poliklinigi Merkez/Nigde Phone: +90 505 416 30 35 Fax: +90 388 212 1411 E-mail:
| | - Şükran Köse
- University Of Health Sciences, Tepecik Training and Research Hospital, Infectious Diseases and Clinical Microbiology Clinic, İzmir, Turkey
| | - İlkay Akbulut
- University Of Health Sciences, Tepecik Training and Research Hospital, Infectious Diseases and Clinical Microbiology Clinic, İzmir, Turkey
| | - Hazal Albayrak
- University Of Health Sciences, Tepecik Training and Research Hospital, Infectious Diseases and Clinical Microbiology Clinic, İzmir, Turkey
| |
Collapse
|
37
|
Kaymakoğlu S, Köksal İ, Tabak F, Akarca US, Akbulut A, Akyüz F, Bodur H, Çağatay A, Dinçer D, Esen Ş, Güner R, Gürel S, Köse Ş, Şentürk Ö, Şimşek H, Yamazhan T, Yılmaz Y, Idilman R, Guidelines Study Group VH. Recommendation for treatment of hepatitis C virus infection. Turk J Gastroenterol 2018; 28:94-100. [PMID: 29303106 DOI: 10.5152/tjg.2017.22] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Sabahattin Kaymakoğlu
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - İftihar Köksal
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Fehmi Tabak
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Ulus S Akarca
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Ayhan Akbulut
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Filiz Akyüz
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Hürrem Bodur
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Atahan Çağatay
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Dinç Dinçer
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Şaban Esen
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Rahmet Güner
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Selim Gürel
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Şükran Köse
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Ömer Şentürk
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Halis Şimşek
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Tansu Yamazhan
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Yusuf Yılmaz
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | - Ramazan Idilman
- Turkish Association for the Study of the Liver, İstanbul, Turkey; Viral Hepatitis Society, Ankara, Turkey
| | | |
Collapse
|
38
|
Kahraman H, Tünger A, Şenol Ş, Gazi H, Avcı M, Örmen B, Türker N, Atalay S, Köse Ş, Ulusoy S, Işıkgöz Taşbakan M, Sipahi OR, Yamazhan T, Gülay Z, Alp Çavuş S, Pullukçu H. [Investigation of bacterial and viral etiology in community acquired central nervous system infections with molecular methods]. MIKROBIYOL BUL 2018; 51:277-285. [PMID: 28929964 DOI: 10.5578/mb.57358] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In this multicenter prospective cohort study, it was aimed to evaluate the bacterial and viral etiology in community-acquired central nervous system infections by standart bacteriological culture and multiplex polymerase chain reaction (PCR) methods. Patients hospitalized with central nervous system infections between April 2012 and February 2014 were enrolled in the study. Demographic and clinical information of the patients were collected prospectively. Cerebrospinal fluid (CSF) samples of the patients were examined by standart bacteriological culture methods, bacterial multiplex PCR (Seeplex meningitis-B ACE Detection (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Listeria monocytogenes, Group B streptococci) and viral multiplex PCR (Seeplex meningitis-V1 ACE Detection kits herpes simplex virus-1 (HSV1), herpes simplex virus-2 (HSV2), varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein Barr virus (EBV) and human herpes virus 6 (HHV6)) (Seeplex meningitis-V2 ACE Detection kit (enteroviruses)). Patients were classified as purulent meningitis, aseptic meningitis and encephalitis according to their clinical, CSF (leukocyte level, predominant cell type, protein and glucose (blood/CSF) levels) and cranial imaging results. Patients who were infected with a pathogen other than the detection of the kit or diagnosed as chronic meningitis and other diseases during the follow up, were excluded from the study. A total of 79 patients (28 female, 51 male, aged 42.1 ± 18.5) fulfilled the study inclusion criteria. A total of 46 patients were classified in purulent meningitis group whereas 33 were in aseptic meningitis/encephalitis group. Pathogens were detected by multiplex PCR in 41 patients. CSF cultures were positive in 10 (21.7%) patients (nine S.pneumoniae, one H.influenzae) and PCR were positive for 27 (58.6%) patients in purulent meningitis group. In this group one type of bacteria were detected in 18 patients (14 S.pneumoniae, two N.meningitidis, one H.influenzae, one L.monocytogenes). Besides, it is noteworthy that multiple pathogens were detected such as bacteria-virus combination in eight patients and two different bacteria in one patient. In the aseptic meningitis/encephalitis group, pathogens were detected in 14 out of 33 patients; single type of viruses in 11 patients (seven enterovirus, two HSV1, one HSV2, one VZV) and two different viruses were determined in three patients. These data suggest that multiplex PCR methods may increase the isolation rate of pathogens in central nervous system infections. Existence of mixed pathogen growth is remarkable in our study. Further studies are needed for the clinical relevance of this result.
Collapse
Affiliation(s)
- Hasip Kahraman
- Sabuncuoglu Serefeddin Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Amasya, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Göl Serin B, Köse Ş, Yilmaz O, Yildirim M, Akbulut I, Serin Senger S, Akkoçlu G, Diniz G, Serin S. An evaluation of the effect of ertapenem in rats with sepsis created by cecal ligation and puncture. ULUS TRAVMA ACIL CER 2018; 25:427-432. [PMID: 31475323 DOI: 10.5505/tjtes.2018.26050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Intra-abdominal adhesions are still a major problem which is expected to be reduced by the provision of bacterial decontamination. Various antibiotics have been used to prevent the formation of adhesion in the septic abdomen. This study aims to investigate the efficacy of ertapenem in sepsis of rats induced by cecal ligation and puncture. METHODS Twenty-eight Wistar rats were divided into four groups randomly. In all groups, bacterial peritonitis was created by cecal ligation and puncture method. Group 1 was considered as sham group. Groups 2, 3 and 4 were given, respectively, saline, a single dose of ertapenem and a dose of ertapenem intraperitoneally every day. Intra-abdominal adhesions were assessed seven days after surgery by histopathological examination. Microbiological examination was performed through the ascites obtained. TNF-α was measured from blood taken from rats. RESULTS Adhesion score decreased significantly by the application of ertapenem (p<0.001) and fibrosis scores were found to be significantly lower (p=0.005). Among all groups, the relationship between the decrease in the number of colonies and antibiotics application was not statistically significant (p=0.109). No statistically significant difference was found between the group given a single dose of ertapenem and the group given multiple ertapenem (p=1). CONCLUSION Peritoneal lavage with ertapenem appears to be effective in preventing the adhesion in the septic abdomen. As no difference was detected at the end of a single dose and multiple-dose administration of antibiotics in the adhesion scores, a single dose after surgery seems to be enough. The findings suggest that the results should be evaluated in a clinical trial.
Collapse
Affiliation(s)
- Başak Göl Serin
- Department of Infectious Diseases and Clinical Microbiology, Hopa State Hospital, Artvin-Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, İzmir-Turkey
| | - Osman Yilmaz
- Department of Laboratory Animal Science, Dokuz Eylül University Faculty of Medicine, İzmir-Turkey
| | - Mehmet Yildirim
- Department of General Surgery, University of Health Sciences Bozyaka Training and Research Hospital, İzmir-Turkey
| | - Ilkay Akbulut
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, İzmir-Turkey
| | - Suheyla Serin Senger
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, İzmir-Turkey
| | - Gülgün Akkoçlu
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Tepecik Training and Research Hospital, İzmir-Turkey
| | - Gulden Diniz
- Department of Pathology, University of Health Sciences Tepecik Training and Research Hospital, İzmir-Turkey
| | - Süha Serin
- Department of Emergency Medicine, Urla State Hospital, İzmir-Turkey
| |
Collapse
|
40
|
Köse Ş, Ödemiş I, Çelik D, Gireniz Tatar B, Akbulut I, Çiftdoğan DY. Hepatitis A, B, C and HIV seroprevalence among Syrian refugee children admitted to outpatient clinics. Infez Med 2017; 25:339-343. [PMID: 29286012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Viral hepatitis is the most common cause of serious health problems such as liver cirrhosis and hepatocellular carcinoma (HCC). Leading to immunodeficiency disorders through different mechanisms, Human Immunodeficiency Virus (HIV) causes the development of severe secondary infections. Hepatitis A (HAV) is thought to spread by the faecal-oral route, while Hepatitis B (HBV), Hepatitis C (HCV) and HIV are mostly transmitted vertically during childhood. In our study, we aimed to determine the seroprevalence of HAV, HBV, HCV and HIV among Syrian refugee children who were admitted to outpatient clinics. We conducted a retrospective review of data concerning 171 Syrian children aged between 0-18 years admitted between April 2014 and December 2015 to the outpatient infectious disease clinic of ?zmir Tepecik Training and Research Hospital and the social welfare outpatient clinic for Syrian refugees for reasons other than jaundice. Serum samples from patients were studied for HAV antibody IgG (anti-HAV IgG), HBV surface antigen (HBsAg), antibodies against HBV surface antigen (anti-HBs), antibodies against HBV core antigen (anti-HBc total), HCV antibody (anti-HCV) (anti-HIV) with the ELISA (Enzyme-Linked Immunosorbent Assay) method. In this study 51% of patients were female, with a mean age of 6.52 years among all patients. Six of the 140 patients (4.2%) scanned for HBV among the patients enrolled in the study were HBsAg and anti-HBc total positive and anti-HBs negative. Three patients (2.1%) were HBsAg negative, and anti-HBc total and anti-HBs positive, which indicated they had previously recovered from an HBV infection. HBsAg, anti-HBs, anti-HBc total data for 140 patients (81.9%), anti-HCV data for 109 patients (63.8%), anti-HIV data for 88 patients (51.5%) and HAV IgG data for 86 patients (50.3%) were obtained. Due to migration from regions in Syria where there is no regular follow-up of HBV vaccination in children, HBsAg seroprevalence of refugee children is thought to be higher than in other children in Turkey and anti-HBs positivity is thought to be lower. We expected to see a higher seroprevalence of anti-HCV and anti-HIV in Syria due to the lack of health facilities such as non-regular anti-HCV and anti-HIV screening before blood transfusions and during pregnancy in all regions of Syria. Yet in this study, the anti-HCV, anti-HIV seroprevalence of Syrian refugee children was similar to that in Turkey. According to the results, if the children of asylum seekers are admitted to the national HAV and HBV vaccination schedule, hepatitis infections and their complications may be prevented.
Collapse
Affiliation(s)
- Şükran Köse
- Division of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Ilker Ödemiş
- Division of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Didem Çelik
- Division of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Bengü Gireniz Tatar
- Division of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Ilkay Akbulut
- Division of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
| | - Dilek Yilmaz Çiftdoğan
- Division of Paediatric Infectious Diseases, Tepecik Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
41
|
Ersan G, Köse I, Liv F, Gireniz Tatar B, Köse Ş. A Case of Cerebral Malaria Managed by Erythrocyte Exchange. Turkiye Parazitol Derg 2017; 41:123-125. [PMID: 28695837 DOI: 10.5152/tpd.2017.4704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Plasmodium falciparum may cause serious and sometimes even fatal cerebral malaria. Cerebral malaria is a disease characterized by alterations in consciousness and epileptic attacks; therefore, it requires a rapid evaluation and quick intervention. It may progress to a fatal outcome despite administering targeted therapeutic interventions. There are studies indicating that erythrocyte exchange (erythrocytapheresis) can be a treatment modality for managing severe malaria patients. In this case report, the successful management of a cerebral malaria patient by the combination of antimalarial drug therapy and erythrocyte exchange is presented.
Collapse
Affiliation(s)
- Gürsel Ersan
- Tepecik Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, İzmir, Türkiye.
| | | | | | | | | |
Collapse
|
42
|
Bülbül Maraş G, Kocaçal Güler E, Eşer İ, Köse Ş. Knowledge and practice of intensive care nurses for endotracheal suctioning in a teaching hospital in western Turkey. Intensive Crit Care Nurs 2016; 39:45-54. [PMID: 27876409 DOI: 10.1016/j.iccn.2016.08.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 08/16/2016] [Accepted: 08/21/2016] [Indexed: 11/15/2022]
Abstract
OBJECTIVES This study was conducted to determine intensive care nurses' knowledge and practice levels regarding open system endotracheal suctioning and to investigate if there is a relationship between nurses' demographic characteristics and their knowledge and practice. RESEARCH METHODOLOGY/DESIGN The study was conducted as a cross-sectional and non-participant structured observational design. Data were collected using a 45-item structured and self-administered questionnaire and a 31-item observational checklist. The study sample included 72 nurses. SETTING Three adult intensive care units in a teaching hospital. RESULTS The nurses' mean scores of knowledge and practice were 23.79±3.83 and 12.88±2.53. Their level of knowledge was very good in 59.7%, good in 34.7%, and the level of practice was fair in 79.2% and good in 18.1%. The relationship between the type of unit and the nurses' knowledge scores was statistically significant (p=0.013). The correlation between the nurses' scores of knowledge and practice was not statistically significant (r=0.220; p=0.063). CONCLUSION This study suggests that the knowledge level of most of the nurses was good and their practice level was fair. Intensive care nurses must perform suctioning procedures safely and effectively to ensure delivery of quality of care and eliminate complications.
Collapse
Affiliation(s)
| | | | - İsmet Eşer
- Department of Fundamentals of Nursing, Ege University, Faculty of Nursing, İzmir, Turkey
| | - Şükran Köse
- Tepecik Education and Research Hospital, Clinical Microbiology and Infectious Diseases Unit, İzmir, Turkey
| |
Collapse
|
43
|
Abstract
Hepatitis B and C virus infections are known to be an important health problem all over the World. According to the data from World Health Organization, 350 million people are estimated to have been chronically infected by hepatitis B virus and 180 million people have been infected by hepatitis C virus. Most of the patients are not aware of their illnesses. Hepatitis B and C virus infections are the most common cause of sequel liver disease related to decompensate liver cirrhosis and hepatocellular carcinoma. Many people are obliged to leave their country due to political, economic and social reasons. In Turkey, where there is refugee and asylum seeker problem because of geographical location, we aimed to specify the demographic characteristics of asylum seekers in Izmir and to evaluate the asylum seekers in terms of blood-borne and sexually transmitted diseases such as hepatitis B and C.
Collapse
Affiliation(s)
- Şükran Köse
- Infectious Diseases and Clinical Microbiology, Tepecik Education and Research Hospital, Izmir, Turkey
| | | | | | | |
Collapse
|
44
|
Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016; 33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 09/30/2015] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Before the introduction of direct-acting antivirals in the treatment of chronic hepatitis C patients, the combination of peginterferon alpha and ribavirin was the standard therapy. Observational studies that investigated sustained virological response (SVR) rates by these drugs yielded different outcomes. AIMS The goal of the study was to demonstrate real life data concerning SVR rate achieved by peginterferon alpha plus ribavirin in patients who were treatment-naïve. STUDY DESIGN A multicenter, retrospective observational study. METHODS The study was conducted retrospectively on 1214 treatment naïve-patients, being treated with peginterferon alpha-2a or 2b plus ribavirin in respect of the current guidelines between 2005 and 2013. The patients' data were collected from 22 centers via a standard form, which has been prepared for this study. The data included demographic and clinical characteristics (gender, age, body weight, initial Hepatitis C virus RNA (HCV RNA) level, disease staging) as well as course of treatment (duration of treatment, outcomes, discontinuations and adverse events). Renal insufficiency, decompensated liver disease, history of transplantation, immunosuppressive therapy or autoimmune liver disease were exclusion criteria for the study. Treatment efficacy was assessed according to the patient's demographic characteristics, baseline viral load, genotype, and fibrosis scores. RESULTS The mean age of the patients was 50.74 (±0.64) years. Most of them were infected with genotype 1 (91.8%). SVR was achieved in 761 (62.7%) patients. SVR rate was 59.1% in genotype 1, 89.4% in genotype 2, 93.8% in genotype 3, and 33.3% in genotype 4 patients. Patients with lower viral load yielded higher SVR (65.8% vs. 58.4%, p=0.09). SVR rates according to histologic severity were found to be 69.3%, 66.3%, 59.9%, 47.3%, and 45.5% in patients with fibrosis stage 0, 1, 2, 3 and 4, respectively. The predictors of SVR were male gender, genotype 2/3, age less than 45 years, low fibrosis stage, low baseline viral load and presence of early virological response. SVR rates to each peginterferon were found to be similar in genotype 1/4 although SVR rates were found to be higher for peginterferon alpha-2b in patients with genotype 2/3. The number of patients who failed to complete treatment due to adverse effects was 33 (2.7%). The number of patients failed to complete treatment due to adverse effects was 33 (2.7%). CONCLUSION Our findings showed that the rate of SVR to dual therapy was higher in treatment-naïve Turkish patients than that reported in randomized controlled trials. Also peginterferon alpha-2a and alpha-2b were found to be similar in terms of SVR in genotype 1 patients.
Collapse
Affiliation(s)
- Yunus Gürbüz
- Department of Infectious Diseases and Clinical Microbiology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Necla Eren Tülek
- Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
| | - Emin Ediz Tütüncü
- Department of Infectious Diseases and Clinical Microbiology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Süda Tekin Koruk
- Department of Infectious Diseases and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Turkey
| | - Bilgehan Aygen
- Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Neşe Demirtürk
- Department of Infectious Diseases and Clinical Microbiology, Afyon Kocatepe University Faculty of Medicine, Afyonkarahisar, Turkey
| | - Sami Kınıklı
- Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
| | - Ali Kaya
- Department of Infectious Diseases and Clinical Microbiology, Mersin University Faculty of Medicine, Mersin, Turkey
| | - Taner Yıldırmak
- Department of Infectious Diseases and Clinical Microbiology, Okmeydanı Training and Research Hospital, İstanbul, Turkey
| | - Kaya Süer
- Department of Infectious Diseases and Clinical Microbiology, Near East University Faculty of Medicine, Nicosia, North Cyprus
| | - Fatime Korkmaz
- Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey
| | - Onur Ural
- Department of Infectious Diseases and Clinical Microbiology, Selçuk University Faculty of Medicine, Konya, Turkey
| | - Sıla Akhan
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Özgür Günal
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey
| | - Nazan Tuna
- Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, İzmir, Turkey
| | - İbak Gönen
- Department of Infectious Diseases and Clinical Microbiology, Süleyman Demirel University Faculty of Medicine, Isparta, Turkey
| | - Bahar Örmen
- Department of Infectious Diseases and Clinical Microbiology, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey
| | - Nesrin Türker
- Department of Infectious Diseases and Clinical Microbiology, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey
| | - Neşe Saltoğlu
- Department of Infectious Diseases and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
| | - Ayşe Batırel
- Department of Infectious Diseases and Clinical Microbiology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
| | - Günay Tuncer
- Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
| | - Cemal Bulut
- Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
| | - Fatma Sırmatel
- Department of Infectious Diseases and Clinical Microbiology, Abant İzzet Baysal University Faculty of Medicine, Bolu, Turkey
| | - Asım Ulçay
- Department of Infectious Diseases and Clinical Microbiology, GATA Haydarpaşa Training and Research Hospital, İstanbul, Turkey
| | - Ergenekon Karagöz
- Department of Infectious Diseases and Clinical Microbiology, GATA Haydarpaşa Training and Research Hospital, İstanbul, Turkey
| | - Derviş Tosun
- Department of Infectious Diseases and Clinical Microbiology, Ulus State Hospital, Ankara, Turkey
| | - Alper Şener
- Department of Infectious Diseases and Clinical Microbiology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey
| | - Aynur Aynıoğlu
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Elif Sargın Altunok
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| |
Collapse
|
45
|
Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Med J 2015; 32:266-72. [PMID: 26185714 DOI: 10.5152/balkanmedj.2015.15366] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 01/11/2015] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The use of pegylated interferon alpha and ribavirin (PegIFN/RBV) for the retreatment of chronic hepatitis C virus (HCV) infection without a sustained virological response (SVR) prior to PegIFN/RBV treatment has resulted in low success rates. AIMS To investigate the efficacy and safety of telaprevir (TVR) in combination with PegIFN/RBV in patients infected with HCV genotypes 1 and 4 who were previously treated with PegIFN/RBV and failed to achieve SVR. STUDY DESIGN Multi-center, retrospective, cross-sectional study. METHODS The study included 111 patients: 80 prior relapsers, 25 prior null responders, and six prior partial responders to PegIFN/RBV treatment. The patients were given TVR/PegIFN/RBV for 12 weeks, followed by a 12-week PegIFN/RBV treatment; virological response results were assessed at weeks 4, 12, and 24. Treatment was discontinued in patients with HCV RNA >1000 IU/mL at week 4 or with negative RNA results at week 4 but >1000 IU/mL at week 12. Rapid virological response (RVR), early virological response (EVR), extended rapid virological response (eRVR), and virological response at 24th week of treatment were evaluated. The side effects of combination therapy and the rates of treatment discontinuation were investigated. RESULTS The mean age of the patients was 56.02±9.96 years and 45.9% were male. Ninety-one percent of the patients were infected with viral genotype 1, 69.6% with the interleukin (IL) 28B genotype CT and 20.2% were cirrhotic. The RVR rate was 86.3% in prior relapsers, 56% in prior null responders, and 50% in prior partial responders (p=0.002). EVR rates in those groups were 91.3%, 56%, and 83.3%, respectively (p<0.001). eRVR rates were 83.8% in prior relapsers, 48% in prior null responders, and 50% in prior partial responders (<0.001). The virological response at the 24th week of treatment was found to be the highest in prior relapsers (88.8%); it was 56% in prior null responders and 66.7% in prior partial responders (p<0.001). Common side effects were fatigue, headache, anorexia, malaise, anemia, pruritus, dry skin, rash, dyspepsia, nausea, pyrexia, stomachache, and anorectal discomfort. All treatments were discontinued due to side effects in 9.9% of patients. CONCLUSION High virological response rates were obtained with TVR/PegIFN/RBV treatment. Although side effects were frequently observed, the discontinuation rate of combination therapy was low.
Collapse
Affiliation(s)
- Bilgehan Aygen
- Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Orhan Yıldız
- Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Sıla Akhan
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Mustafa Kemal Çelen
- Department of Infectious Diseases and Clinical Microbiology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Onur Ural
- Department of Infectious Diseases and Clinical Microbiology, Selçuk University Faculty of Medicine, Konya, Turkey
| | - Süda Tekin Koruk
- Department of Infectious Diseases and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Turkey
| | - Şükran Köse
- Department of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, İzmir, Turkey
| | - Fatime Korkmaz
- Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey
| | - Ziya Kuruüzüm
- Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylül University Faculty of Medicine, İzmir Turkey
| | - Nazan Tuna
- Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey
| | - Serpil Taheri
- Department of Medical Biology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Murat Sayan
- Clinical Laboratory, PCR Unit, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Nazlım Aktuğ Demir
- Department of Infectious Diseases and Clinical Microbiology, Selçuk University Faculty of Medicine, Konya, Turkey
| | - Şua Sümer
- Department of Infectious Diseases and Clinical Microbiology, Selçuk University Faculty of Medicine, Konya, Turkey
| | - Elif Sargın Altınok
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| |
Collapse
|
46
|
Köse Ş, Serin Senger S, Akkoçlu G, Kuzucu L, Ulu Y, Ersan G, Oğuz F. Clinical manifestations, complications, and treatment of brucellosis: evaluation of 72 cases. Turk J Med Sci 2015; 44:220-3. [PMID: 25536728 DOI: 10.3906/sag-1112-34] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
AIM Brucellosis is an important disease in developing countries. We aimed to determine the epidemiologic, clinical, and laboratory characteristics of brucellosis, which still has a high morbidity in Turkey. MATERIALS AND METHODS Seventy-two patients with brucellosis, monitored at our clinic from January 2004 to July 2010, were reviewed retrospectively. RESULTS The average age was determined to be 44.8 ± 18 years, and 40 of the patients were female (55.6%). The most frequent transmission route was the use of raw milk and dairy products, in 45 of the patients (62.5%). The most frequent complaints were joint pain, high fever, weakness, low back pain, and gastrointestinal symptoms, whereas the most frequent physical examination findings were fever, osteoarticular involvement, splenomegaly, hepatomegaly, and lymphadenopathy. All of the patients were positive for Rose Bengal testing. The standard tube agglutination titer was 1/160 or higher in 64 (88.9%) patients. Brucella melitensis was isolated from blood cultures of 13 (18.1%) patients and bone marrow cultures of 7 (9.7%) patients. Complications of sacroiliitis in 6 (8.3%), spondylodiscitis in 4 (5.6%), endocarditis in 2 (2.8%), neurobrucellosis in 1 (1.4%), and epididymo-orchitis in 1 (1.4%) of the patients were observed. CONCLUSION Brucellosis has various clinical presentations. It should be included in the differential diagnosis of high fever and joint pains in endemic countries.
Collapse
|
47
|
Köse Ş, Türken M, Taşlı F, Çolak H, Göl Serin B. Staphylococcal empyema secondary to IgA nephropathy. CEN Case Rep 2014; 3:195-197. [PMID: 28509200 DOI: 10.1007/s13730-014-0116-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2013] [Accepted: 03/03/2014] [Indexed: 11/24/2022] Open
Abstract
A 27-year-old male patient, applied to the emergency unit with complaints of high fever, nausea, vomiting, and hematuria. In his physical examination, fever was 38 °C with normal findings in all other systems. The laboratory values were as follows: urea 58 mg/dL, creatinine 2.4 mg/dL, white blood cell count 15.9K/μL (PNL: 79 %). In his urine analysis; +1 proteinuria and +3 hematuria were detected. Kidney biopsy was performed. Kidney biopsy interpreted in favor of IgA nephropathy. As the patient had tonic-clonic seizures, cranial CT examination was performed. In the cranial CT, there was a subdural effusion in the anterolateral area of the right cerebral hemisphere with the left shift in the midline secondary to the effusion. Empyema fluid, which was drained postoperatively, was cultured. In the direct examination of the empyema fluid, Gram positive cocci and abundant amount of PNLs were observed. There was no growth in the culture. Although the most commonly encountered agents for post-infectious glomerulonephritis are streptococcus infections, it has been reported that glomerulonephritis attacks may be rarely observed due to staphylococcus infections. Proliferative glomerulonephritis cases are rarely encountered conditions characterized by mesangial IgA accumulations secondary to staphylococcus infections.
Collapse
Affiliation(s)
- Şükran Köse
- Infectious Disease and Clinical Microbiology, İzmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Melda Türken
- Infectious Disease and Clinical Microbiology, İzmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Funda Taşlı
- Infectious Disease and Clinical Microbiology, İzmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Hülya Çolak
- Infectious Disease and Clinical Microbiology, İzmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Başak Göl Serin
- Infectious Disease and Clinical Microbiology, İzmir Tepecik Training and Research Hospital, Izmir, Turkey.
| |
Collapse
|
48
|
Gençcelep H, Andiç S, Köse Ş. Effects of Potassium Sorbate Application on Shelf Life and Biogenic Amines of Pearl Mullet (Chalcalburnus tarichiPallas, 1811) Fillets Packaged With Vacuum. Journal of Aquatic Food Product Technology 2014. [DOI: 10.1080/10498850.2012.719588] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Köse Ş, Mandıracıoğlu A, Çavdar G, Ulu Y, Senger SS. Prevalence of allergic diseases in Izmir Province, Turkey. Int Forum Allergy Rhinol 2014; 4:232-8. [PMID: 24470196 DOI: 10.1002/alr.21263] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 09/26/2013] [Accepted: 11/05/2013] [Indexed: 01/17/2023]
Abstract
BACKGROUND The aim of the present study is to determine the prevalence of allergic diseases and related risk factors in Izmir, Turkey, and to assess the positive immunoglobulin E (IgE) levels against common allergens. METHODS The questionnaires were completed via face-to-face interview with a total of 2937 individuals. Specific IgE was studied in the serum samples by enzyme-linked immunosorbent assay (ELISA). This cross-sectional population-based study comprised adolescents over the age of 15 years and adults of Izmir province. RESULTS In Izmir, the prevalence of self-reported allergy was 35.5%. Allergy was statistically significantly more common in females, university graduates, in those with high income, with family history for allergy, aged 40-49 years, those living in a flat, keeping pet(s), and in those using central heating. The prevalence of atopy according to the serum IgE levels (Class 3 with any of 3 IgEs) was found 1.6%. CONCLUSION In conclusion, the prevalence of atopy was found lower in Izmir as compared to the results of other studies.
Collapse
Affiliation(s)
- Şükran Köse
- Tepecik Educational and Research Hospital, Infectious Diseases and Clinical Microbiology, Allergy and Immunology Clinic, Izmir, Turkey
| | | | | | | | | |
Collapse
|
50
|
Köse Ş, Ersan G, Serin Sender S, Devrim İ, İnal MM. A prevalence study of Chlamydia infections in Turkish population. Braz J Infect Dis 2013; 17:114-5. [PMID: 23294642 PMCID: PMC9427365 DOI: 10.1016/j.bjid.2012.07.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Revised: 07/24/2012] [Accepted: 07/25/2012] [Indexed: 11/19/2022] Open
|